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Cancer is one of the leading causes of death in Norway (2016) and worldwide. Despite the 
advent of new immunotherapies, malignant cancer demonstrates an intrinsic plasticity and is 
able to evade, adapt and suppress the immune system. An important driver for this malignant 
phenotype is the epithelial-to-mesenchymal transition (EMT) program, characteristic of stem 
cells. Previous research showed a link between the AXL receptor tyrosine kinase (Axl) and 
EMT. The Axl receptor is further involved in immune suppression and could therefore serve as 
a potential target in immunotherapy and in combination with other cancer treatments. 
Chemotherapeutic treatment also shows evidence of immune involvement, and the immune 
system plays a vital role in all forms of cancer treatment. In this study, we evaluated current 
immunotherapy in combination the Axl kinase inhibitor, bemcentinib. Using single cell mass 
cytometry we conducted 30 parameter mapping of the immune system in an experimental 
murine tumour model. The data was analysed using dimensionality reduction and 
unsupervised clustering. By studying how the immune landscape changes during tumour 
development and immunotherapy treatment, important insights into how the immune system 
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BSA Bovine serum albumin 
CTL Cytotoxic T lymphocyte 
CTLA-4 Cytotoxic T-lymphocyte-associated protein 4 
CVD Cardiovascular diseases 
CWB Cell washing buffer 
CyTOF Cytometry by time-of-flight 
DNA Deoxyribonucleic acid 
DOTA 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DPBS Dulbecco’s PBS 
DTPA Polymeric pentetic acid 
EMP Epithelial-to-mesenchymal plasticity 
EMT Epithelial to mesenchymal transition 
ICB Immune checkpoint blockade 
MDSC Myeloid derived suppressor cell 
MHC Major histocompatibility complex 
NaAz Sodium Azide 
NK Natural Killer 
PBS Phosphate buffered saline 
PD-1 Programmed cell death protein 1 
PP Polypropylene 
RCF Relative centrifugal force  
RF Radio frequency 
RT Room temperature 
TAM Tumour associated macrophage 
TCEP tris(2-carboxyethyl)phosphine 
TCR T cell receptor 
Th Helper T cell 
TIL Tumour infiltrating lymphocyte 




Angiogenesis Formation of new blood vessels from existing ones 
Anoikis Avoiding detachment-induced apoptosis 
Antigens A molecule that can be bound by an antibody and initiate an 
immune response. 
Apoptosis A form of nonimmunogenic controlled cell death.  
Cell differentiation  When a cell goes from one cell type to another and quires 
different traits.  
Immunogenic  A process capable of initiating an immune response.  
Immunotherapy The use of the immune system to treat cancer 
Intercalator A molecule that can be inserted between base pairs in DNA. 
Leukocytes White blood cells comprising the immune system. 
Mahalanobis distance A type of distance used in multivariate space to find the 
distance from the centroid to a given point. The centroid is the 
point where the means of all variables intersect. 
MilliQ A type of purified water. 
Mutation  Permanent change in nucleotide sequence, either by insertion, 
deletion or substitution of a single nucleotide. 
Neoantigens New antigens. 
Push A single slice of the gas stream in the TOF chamber. 
Reading The integrated intensity of several pushes. 
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1.1 Tumours on a population level 
Cancer is one of the leading causes of death in Norway (2016) [1] and one of the leading causes 
worldwide [2]. In addition, tumour-related deaths have been steadily increasing and will 
continue to rise (see Figure 1.1). Tumour incidence is also increasing in Norway and in 2017 
almost 34’000 new cases were registered [3]. In 2014, the total costs, including treatment and 
loss of production, was estimated to be 40 billion NOK [4]. The treatment and care alone were 
estimated to cost 20 billion NOK, while the loss of production due to sick leave and death was 
estimated to be 18 billion NOK. Further, the accumulated risk of a cancer diagnosis during a 
lifetime of 75 years is about 30% for women and 36% for men [3]. Cancer therefore represents 
a significant economical and emotional burden to the society.  
 
Figure 1.1: Top five causes of death in Norway. In 2016 tumours passed cardiovascular diseases and became the number one 
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One of the main risk factors for cancer is age; 3 out of 4 new cancer cases are attributed to 
adults over 60 years old. Thus, it is expected that cancer incidence will increase as life 
expectancy increases. The inherent heterogeneity and plasticity of cancer complicates 
treatment. After an initial therapy efficacy, tumours inevitably develop resistance, after which 
treatment options are limited or non-existent [5]. 
1.2 Cancer development 
Cancer is a genetic disease caused by gene mutations. Mutations occur naturally during DNA 
replication and as a result of exposure to carcinogens. The role of replication errors is evident 
from the correlation between cancer risk and number of stem cell divisions in the tissues [6]. 
Tomasetti et al. estimated that three mutations occur every time a human stem cell divides. 
Although apparently negligible within a human genome of three billion base pairs [7], the 
accumulated risk of mutating an important gene significantly increases by taking into 
considerations the number of divisions required to create the trillions of cells that make up a 
human body. Mutations arising due to environmental factors have also been extensively 
shown; the correlation between melanomas and sunburns, and smoking and lung cancer are 
well characterised [8, 9].  
Mutations can affect proteins in several ways; it can alter protein expression, structure, and 
function. Mutations in oncogenes, such as growth factor receptors, promote cell survival and 
immortality. Oncogenic mutations drive uncontrolled cellular growth creating in situ tumours 
consisting of cellular clones from the original transformed cell. New mutations that further 
increase tumour cell fitness lead to evolution of the tumour. This selection process favours 
genomic instability that increases mutational rates. As a tumour develops it can therefore 
consist of several different cell populations (heterogeneity), all originating from the cancer 
cell-of-origin. Tumour growth also results in a modified microenvironment comprising altered 
blood vessels, connective tissue, extracellular matrix and immune infiltrate. Malignant tumour 
cells can invade adjacent tissues and spread throughout the body (metastasis) [10].  
1.2.1 Malignancy and EMT 
According to Hanahan and Weinberg six traits (hallmarks) of cancer cells exist [11]. These traits 
are: growth signal independence, insensitivity to anti-growth signals, evasion of programmed 




(angiogenesis), and tissue invasion and metastasis. In 2011 Hanahan and Weinberg added two 
new emerging hallmarks; deregulating cellular energetics and avoiding immune detection, 
and two new enabling characteristics; genome instability and mutation, and tumour 
promoting inflammation [12]. These hallmarks are further used as targets for cancer 
treatment.  
Epithelial-to-mesenchymal plasticity (EMP), consisting of both the epithelial-to-mesenchymal 
transition (EMT) and mesenchymal-to-epithelial transition (MET), is regulated by a highly 
coordinated complex network of transcription factors and epigenetics [13]. Best known for 
formation of the mesoderm during early development, this cellular plasticity supports changes 
in cell phenotype, providing cells with new characteristics and functions. EMT-like processes 
are important in a number of physiological processes in addition to embryonic development, 
including wound healing, fibrosis, and organ formation [14]. In cancer cells EMT has been 
associated with invasion, avoiding detachment-induced apoptosis (anoikis), resistance to 
chemotherapy, immune escape, dissemination and resistance to apoptosis (see Figure 
1.2)[14-20]. It is therefore considered a major player in enabling cancer progression and a 





Figure 1.2: Process of metastasis. Normal epithelium sits regularly on a basement membrane. Abnormal differentiation and 
growth, known as dysplasia, then develops. After further accumulation of epigenetic and genetic mutations, a carcinoma in 
situ is formed. The cells have still not broken through the basement membrane, but the carcinoma in situ cells have the 
potential to engender this ability. One way for cells to acquire this ability is through the epithelial–mesenchymal transition 
(EMT). The carcinoma in situ is then referred to as invasive carcinoma. The invasive cells enter the lymph or blood vessels and 
may use these to travel to distant parts of the body. By using the transformation opposite to EMT, the mesenchymal–epithelial 
transition (MET), the cells can form micro metastases and create a new tumour environment. Upon further differentiation, 
macro metastases may form. Picture is reprinted from Thiery’s review “Epithelial–mesenchymal transitions in tumour 
progression” [21]. 
The expression of AXL receptor tyrosine kinase, is induced by transcription factors important 
in EMT [22]. Studies show that Axl regulates tumour growth, proliferation, invasiveness and 
drug resistance and immune evasion [23-25]. In human mammary epithelial cells, EMT 
transcription factors induce expression of Axl [22]. Gjerdrum, C., et al., showed that breast 
cancer cells generate an autocrine loop with the ligand for Axl, Gas6. The same study showed 
that knockdown of Axl blocked dissemination of the cancer cells to several organs. This link 
between Axl and EMT was subsequently demonstrated in several other cancer cell types. 
Hence, Axl has emerged as an important drug target to prevent metastasis and reverse drug 
resistance. Down regulation of Axl expression by knocking out the Axl regulator vimentin 
demonstrated that Axl plays an important role in migration of breast cancer lines [24]. 
Treatment with the Axl inhibitor, bemcentinib (BGB324/R428), blocked breast cancer cell 
metastasis in breast cancer models. Inhibition of Axl has also been shown to revert EMT in 
different cancer models [26, 27].  
1.2.2 Immunosuppression 
In all nucleated cells, proteins are continuously degraded to peptides by the proteasome. The 
major histocompatibility complex type I (MHC I) protein has a binding site “groove” that will 
bind one of these peptides, called antigens, and present it at the cell surface. This allows 
cytotoxic T lymphocytes (CTLs) to probe each cell for the presence of non-self antigens (e.g. 
produced by a virus), by binding the MHC I with their T cell receptors (TCRs). If the CTL is 
mature and the TCR recognises the peptide antigen as non-native on the MHC I groove it can 
initiate an attack on the cell and kill it. 
Several prerequisites are necessary for the CTLs to be able to kill tumour cells. These steps are 
known as the tumour immunity cycle and is summarised in Figure 1.3. Firstly, tumour cells 
with must have non-native “neoantigens”- mutated proteins- that are released and 
phagocytosed by a professional antigen presenting cells (pAPC) and degraded in its 




neoantigen to naïve T and B cells using both MHC II molecules and in MHC I molecules. During 
antigen presentation, helper T cells (Th) and CTLs will bind the MHC II and MHC I molecules 
respectively with their cell receptors. If the binding affinity is high enough and the pAPC in 
addition expresses co-stimulatory proteins, such as CD80 and CD86, T cells can mature and 
become active.  
CD80 and CD86 bind CD28, expressed on naïve T cells, and is necessary for their activation. 
Post-activation, CD28 expression is decreased and cytotoxic T-lymphocyte-associated protein 
4 (CTLA-4; CD152) expression is increased. CTLA-4 binds the same proteins as CD28, but with 
higher affinity and avidity, and, as opposed to CD28, CTLA-4 is a suppressive molecule 
inhibiting CTLs and Ths. This creates the basis for anti-CTLA-4 immunotherapy where the 
suppression through CTLA-4 is mitigated [28, 29]. 
After Ths have been activated they can proceed to activate B cells or home to the inflamed 
tissue along with CTLs. Activated B cells can secrete antibodies that bind surface antigens on 
the tumour cells. These antibodies can subsequently allow granulocytes, NK cells and 
macrophages to attack cancer cells. For the T cells to be able to infiltrate the tumour, the 
endothelial cells lining blood vessels must express adhesion molecules that allow T cell 
infiltration. These adhesion molecules are tissue and inflammation dependent. Thus, if the 
tumour prevents proper maturation blood vessels or expression of adhesion molecules, T cell 
infiltration is impaired [30]. If the lymphocytes are able to infiltrate the tumour tissue, they 
must then find tumour cells presenting the same specific neoantigen, as used for their 
activation, before an attack can commence. An attack of the CTLs on tumour cells will result 
in lysis of the tumour cell and release of more antigens. These antigens can then be digested 





Figure 1.3: The tumour immunity cycle. A cyclic process of digestion of tumour cell antigens, T cell activation and cancer cell 
killing. The term antigen presenting cells (APCs) is in this case used to refer to professional antigen presenting cells. Reproduced 
from [31]. 
Even if tumour cells are discovered, the attack can be suppressed by activating suppressive 
molecules on the T cells, such as programmed cell death protein 1 (PD-1; CD279), by 
expressing one of its ligands PD-L1 or PD-L2 (programmed death-ligand 1 and 2; CD274, 
CD273). This creates the basis for anti-PD-1 immunotherapy where the suppression through 
PD-1 is mitigated [29, 32]. 
In addition, tumours can recruit regulatory T cells, regulatory B cells, myeloid derived 
suppressor cells (MDSCs) and suppressive tumour associated macrophages type 2 (TAM2) to 
aid in tumour growth and immune suppression. Of note, the polarisation of macrophages to 
the TAM2 phenotype has been related to AXL [33]. TAM2 cells have been shown to promote 
angiogenesis, secrete growth factors and suppress the adaptive immune response [34]. 
Blocking the TAM2s through AXL-inhibition can potentially improve existing immune 






Figure 1.4: Overview of AXL’s involvementin immune evasion. Dots represent various stimulatory or inhibitory cytokines. 1. 
Dendritic cells can present neoantigens from ingested tumour cells and activate T cells. 2. Activated T cells can aid in killing 
tumour cells presenting the same neoantigen as used for their activation. NK cells and tumour associated macrophages type 
1 (M1) do not need neoantigens for activation, but instead need stimulatory molecules. 3. Tumour associated macrophages 
type 2 (M2) can suppress the immune response through activation of AXL and secretion of its ligand, Gas6. bemcentinib should 
inhibit this suppression. 4. Tumour cells can switch from an epithelial phenotype to a mesenchymal-like phenotype through 
activation of AXL. Bemcentinib can inhibit and reverse this transition. Tumour cells can also express inhibitory molecules such 
as PD-L1 and prevent CTLs from attacking them. Adapted from BerGenBio poster [35].  
The immune system is, however, not solely dependent on the display of neoantigens. Often, 
tumour cells downregulate the display MHC I molecules by dysregulating parts of the antigen 
presentation cycle. Despite not displaying antigens, natural killer (NK) cells use the MHC I 
molecules as a negative regulator and cell stress markers as positive regulators to decide 
whether to eliminate a cell. Cancer cells that present stress induced ligands and have low 
amounts of MHC I are therefore targeted and killed by NK cells [36].  
1.3 Treatment of Breast Cancer 
Treatment of breast cancer in Norway is based on guidelines developed by Norwegian Breast 
Cancer Group. Every year new guidelines are published. As of 2018, first line treatment for 
curative patients is surgical removal of the tumour and nearby affected tissue as well affected 
ipsilateral axillary lymph nodes. Depending on tumour and patient characteristics, patients 




therapy for hormone receptor positive tumours and Her2 overexpressing tumours. Patients 
with distant metastasis or inoperable tumours at diagnosis can be treated with several lines 
of palliative chemo-radiation and targeted therapy [37]. 
1.3.1 Anti-PD-1 and Anti-CTLA-4 
Immunotherapy aids the immune system in attacking tumour cells. Two common 
immunotherapies are the anti-PD-1 and the anti-CTLA-4 immunotherapies (comprising the 
immune checkpoint blockade), as noted in section 1.2.2 [29]. These therapies are given as 
antibodies that bind the functional domains and prevent activation. Anti-PD-1 and anti-CTLA-
4 have both been proven effective in treatment of melanoma and lung cancer[38, 39]. In 
addition, an increased effect is seen during combination [40]. In breast cancer, anti-PD-1 
shows some effect in advanced patients with triple negative disease, while anti-CTLA-4 shows 
minimal effect [41]. 
CTLA-4 is a suppressive molecule expressed on CTLs and Ths, while PD-1 is a suppressive 
molecule upregulated on activated CTLs and Ths. In addition, CTLA-4 and PD-1 tends to be 
upregulated on Tregs, where it may enhance suppressive function and proliferation 
respectively [29]. With the use of antibodies inhibiting activation of these proteins it is 
expected an increase of the CTL and the Th population.  
1.3.2 Bemcentinib  
Bemcentinib (Figure 1.5) is a small molecule that binds the ATP pocket of the Axl kinase, 
inhibiting autophosphorylation and thus receptor activation [27]. As noted in section 1.2.1, 
AXL expression is associated with EMT, immune evasion and poor patient survival. In addition, 
the TAM2 immune suppressive phenotype has been related to Axl. Bemcentinib can thus 
potentially function as an anti-immune suppressive drug.  
 
 
Figure 1.5: Molecular structure of bemcentinib. Bemcentinib works by blocking autophosphorylation and selectively inhibiting 
the phosphorylation site tyrosine kinase domain of the receptor tyrosine kinase AXL[27]. Structure is drawn by Wikipedia user 




1.3.3 Combination of Bemcentinib and Immunotherapy 
Bemcentinib in combination with Keytruda (anti-PD-1) is currently in phase II trials on triple 
negative breast cancer patients [42]. The increased efficacy of immunotherapy-bemcentinib 
combination has also been shown in preclinical trials (see Figure 1.6) [35]. Mice harbouring 
mammary adenocarcinomas with a combination of bemcentinib and anti CTLA-4 and anti-PD-
1, comprising the immune checkpoint blockade (ICB), resulted in a significantly increased 
survival. 
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Figure 1.6: Preclinical survival study studying a combined treatment of bemcentinib and immunotherapy.Pooled data from 
two independent survival analyses of BALB/C mice implanted with 4T1 breast cancer cells. Upon reaching a tumour volume of 
500 mm3 the mice were registered as non-survivors. The mice were given treatments with control (vehicle), bemcentinib 
(BGB324), anti CTLA-4 and anti-PD-1 combination (ICB), or a combination of bemcentinib and ICB. Figure is reprinted from 
[35] 
The mechanism behind this result is, however, poorly characterized. 
1.4 Aims and Objectives 
As discussed in the previous sections, cancer is one of the leading causes of death in Norway 
and one of the leading causes of deaths worldwide. Malignant cancer has an intrinsic plasticity 
driving therapy resistance, and immune system suppression. An important driver for this 
malignant phenotype is the EMT program. Earlier research indicates a link between AXL, EMT 
and immune suppression in tumours. Combined immune checkpoint and AXL-inhibitor 
therapy bemcentinib demonstrated a synergistic effect. We therefore endeavoured to 





Figure 1.7: Methods summary. A: Spleen and tumours were collected at two different timepoints from mice in four different 
treatment groups. B: The tissues were dissociated to single cells, fixed and frozen for storage. The samples were later stained 
and C: run on the mass cytometer. D: After data acquisition the data was analysed with regular gating, high dimensional 
analyses and statistics. The depicted stained single cell is adapted from [43] and the mass cytometer is reproduced from [44]. 
To investigate how this combination affects the tumour immune response we harvested 
tumour and spleen tissue from tumour bearing mice at different timepoints treated with 
vehicle, bemcentinib, immune checkpoint blockade, or a combination of bemcentinib and 
immune checkpoint blockade. These tissues were dissociated to single cells and analysed by 
mass cytometry, an approach that allows for measurement of multiple proteins on single cells. 
High dimensional analyses were used to map the immune landscape across tissues, 
treatments, and timepoints. By studying how the immune landscape changes during tumour 






2 Methodological considerations 
2.1  Mass cytometry 
Mass cytometry is a novel method for analysing multiple parameters in single cells [45]. These 
parameters include, but are not limited to, proteins, lipids, and nucleic acids. The targets on 
the cells are labelled directly or indirectly with heavy metal isotopes before running the 
sample through a mass spectrometer and measuring the metal content single cells.  
A typical chronological staining procedure for mass cytometry is to: 1) use a reagent to 
distinguish between live and dead cells; 2) identify cells or proteins of interest by staining for 
specific proteins with antibodies, and 3) to identify whole cells by staining with a DNA 
intercalator. Depending on the type of experiment and proteins of interest, cells are fixed and 
permeabilised before or after staining with antibodies. 
2.1.1.1 Instrument 
Before data acquisition, the mass cytometer is tuned, a procedure entailing estimation of dual 
count coefficients, calibration of gas flows, and electric voltages over the cones and the 
detector. At the end of the tuning is a quality control is normally required to be passed in order 
to run any experiments.  
The mass cytometer consists of a mass spectrometer coupled with a system to deliver a cloud 
of singly positively charged atoms from a single cell [46, 47]. A schematic of the prototype is 





Figure 2.1: "Schematics of the prototype CyTOF mass cytometer". The sample enters the machine in the lower right corner 
and is made into a mist by the nebuliser. The mist with single cell droplets is heated leading to single cells suspended in gas. 
The cells are then ionised and fully burned in the induction coupled plasma before being filtered by the deflector and the 
quadrupole. The filtered cloud lastly enters the time-of-flight (TOF) chamber where sequential slices of the cloud are launched 
into a parabolic path separating the singly charged atoms based on mass prior to hitting the detector. Reproduced from [46]. 
2.1.1.2 Sample Introduction and Ionisation 
A test tube containing a fixed, stained sample of single cells is placed into the autosampler 
chamber (see Figure 2.2) and a small sample line is inserted into the test tube. Argon gas is 
released into the closed chamber and the increased pressure pushes the sample up the 





Figure 2.2: Fluidigm's mass cytometer model Helios. The Helios differs from other mass cytometer systems by having the 
autosampler instead of a syringe pump to inject the sample. The autosampler can be seen standing on the shelf on the right 
side of the machine. Reproduced from [44]. 
The nebuliser combines the sample with argon and pushes it through a nozzle, creating a mist 
of small droplets, each optimally containing only a single cell. The mist is mixed with more 
argon gas and heated in the spray chamber to evaporate fluid from the droplets, leaving only 
single cells suspended in argon gas. Each cell is then transferred, in a stream of argon, through 
a plasma [44]. 
The plasma is generated by an induction coupled plasma torch. The torch functions by 
applying a spark to the argon gas in an alternating electromagnetic field, created by a coil 
connected to a radio frequency (RF) generator. The oscillating field amplifies the movement 
of the electrons from the spark, increasing the electron collision rate with other atoms and 
molecules and establishes the plasma. The continuously oscillating electromagnetic field 
stabilises the plasma in the flowing argon gas. The temperature of the plasma is about 5000 
kelvin in the core of the stream and 7000 kelvin around the edges [48]. This is comparable to 
the temperature of the surface of the sun. Despite the high temperature, without the 
nebuliser and the heating chamber the cells would not be fully atomised and ionised. Because 
they are already dry and suspended as single cells almost all the molecules in the cells 




charged ions. If the plasma is relatively cool or the argon flow rate is too high, oxides can form 
and lead to +16 dalton spill. This means that a 150Nd tag can be registered as a 166Er tag.  
Electrostatic repulsion and heat from the plasma leads expansion of the atomised cloud. The 
expansion of the cloud dominates over cell size, so that regardless of the cell’s size, the cloud 
expands to approximately 1-2 mm [49]. To prevent cloud expansion, vacuum is needed to cool 
the gas. The vacuum is created by a set four vacuum pumps evacuating the interfaces between 
three cones and the rest of the machine. The first cone extracts 10% of the plasma and 
decreases the pressure from 760 torr to about 2 torr. The second cone only extracts 1% of the 
gas passing the first cone and further decreases the pressure. The last cone transmits 100% of 
the gas from the second cone and has a voltage applied to improve ion transmission before 
being focussed by a lens prior to entering the deflector.  
2.1.1.3 Ion Optics 
The deflector consists of four pillars assembled in the corners of a square. Each pillar has the 
opposite charge of its lateral and vertical neighbour and the same charge as its diagonal 
neighbour. The ions enter from the side, between the front positive and negative pillars. The 
positive ions are pulled toward the negative pillar, but due to their velocity, they travel in a 
curved path and exit 90 degrees to the left (or right depending on the charge of the pillars) of 
where they entered. Neutral particles and photons travel straight through. The removal of 
photons is vital because it is impossible to differentiate a photon from an ion hitting the 
detector. The positive ions are then focused by lenses before entering the quadrupole. In the 
quadrupole, low mass ions (such as argon) are removed and ejected from the stream, leaving 
only atoms with a single positive charge and around 80 daltons. The now filtered cloud of 
singly positive atoms move towards the time of flight (TOF) chamber [46]. 
2.1.1.4 Ion Separation and Detection 
In the TOF chamber sequential vertical slices of the ion stream are launched into a reflector 
creating a parabolic path. The slice of ions ejected from the stream is referred to as a push. 
During the push the force applied to each ion is the same, since they all have the same single 
positive charge, however, the speed they gain is different because the mass of the ions is 
different. The lightest ions will therefore travel faster than the heavier ones and arrive earlier 




estimated based on the time of flight. Due to variability in initial speed and position of the ions 
prior to the push, the ions in each mass packet will spread out and some ions might enter a 
neighbouring mass window. This is referred to as abundance sensitivity and is less than 0.3% 
for 159Tb [50]. Thus if 1000 ions are registered in the 140Ce channel, 3 ions are estimated to 
enter each of the neighbouring mass windows 139La and 141Pr.  
At the end of the parabolic path, a cathode serves as the start of an electron multiplier tube. 
Upon hitting the cathode, electrons are released, but too few are released to be able to 
register, hence the electron multiplier tube is needed. The electrons released from the first 
cathode are accelerated towards the next plate, called dynode, by an electric field. For each 
dynode the electrons hit, the number of released electrons multiplies. At the end of the tube 
an amplifier amplifies the voltage created by the electrons. Since not every electron hits the 
final anode at the same time, the signal is manifested as a pulse. The voltage from the anode 
is amplified and converted to digital signals by an analogue-to-digital converter (ADC) at 1 GHz.  
 
Figure 2.3: Signal pulse overlap Electron pulses are generated when ions hits the detector. A: When few ions hit the detector 
in the same push, the pulses are not overlapping. The ion counts can therefore be found by counting the pulses. B: When more 
ions hit the detector, the pulses can overlap, and the integrated intensity is instead used. The integrated intensity is calculated 
by multiplying the maximum intensity with the width at half maximum. Later on, the integrated intensity is multiplied with 
the dual count coefficient to estimate the true number of ions hitting the detector. Reproduced from [44]. 
When multiple ions hit the detector at the same time or are sufficiently close, the generated 
voltage pulses overlap (see Figure 2.3). This means that the number of ions hitting the detector 
must be approximated based on the generated voltage. Each electron pulse generates a 
voltage pulse lasting a few nanoseconds. To estimate the intensity, the maximum voltage of 
the electron pulse is multiplied by the width of the pulse at half max. Since each ion hitting 
the cathode should release the same number of electrons, a linear relationship between the 





Figure 2.4: Analyte deflection during tuning. As the deflector voltage is altered during tuning the number of ions entering the 
TOF chamber changes. When number of pulses per push is between 0.1 and 1 a linear relationship between true count and 
intensity exists. The slope of the linear fit is called the dual count coefficient. By using this coefficient, the true counts of ions 
hitting the detector can be estimated by multiplying it with the integrated intensity. Reproduced from [51]. 
During tuning the linear correlation between intensity and true count is estimated. This is 
done by running a “tuning solution”, containing the specific heavy metal isotopes 133Cs, 
139La, 155Gd, 159Tb, 169Tm 191Ir, and 193Ir, through the machine. To gradually increase the 
number of ions entering the TOF chamber, the voltage on the deflector (before entering the 
quadrupole) is adjusted. When very few ions hit the detector there is a linear relationship 
between the intensity and the pulse count. This zone is referred to as the zone of dual validity. 
Several readings, each consisting of one or more pushes, are taken and used to plot a curve 
between the pulse counts and the intensity. The zone of dual validity is valid only when pulses 
per push is between 0.1 and 1. In this zone the relationship between intensity and pulse counts 
is linear and a regression is performed to find a dual count coefficient which allows for 
calculation of true counts based on intensity alone (see Figure 2.4). The dual counts are named 
after the dual values it returns. If the number of pulses created in a push is below 0.1 (default 




estimation of true counts based on intensity is returned. At the end of the tuning is a quality 
control where the final signal intensity and oxide generation is checked. If the signal intensity 
is too low or the oxide generation is too high the tuning will not pass.  
2.1.1.5 Data Processing 
Upon starting data collection on the mass cytometer, the masses to record have to be 
manually selected. Even though a mass is not selected for recording, it will still hit the detector 
if it is in the sample. Having determined the dual count coefficient during tuning, dual counts 
for every selected mass in every push is calculated. For each push the dual counts are summed 
over the selected masses. This sum is referred to as total ion current and is used to filter out 
non-single cloud events. The filtering process works by applying a convolutional threshold that 
the total ion current must exceed for at least 10, but not more than 150 pushes. This threshold 
has a standard value of 400, but it can be changed manually. In addition, noise reduction can 
be applied. The noise reduction calculates the mean total ion current between cell events and 
subtracts this value from total ion current measured during a proximal event [49]. If the 
number of pushes in an event, referred to as event length, is between 10 and 150, then a 
gaussian fit will be performed on the total ion current. From this fit, the gaussian parameters 
width, centre, residual, and offset are returned. The event length, width, centre and residual 
can later be used to find single cell events. The offset, however, is poorly described and is not 
commonly used in further analysis. Having characterised an event, the dual count for each 
selected mass is summed over the pushes in the event and saved in a flow cytometry standard 
(fcs) file along with the gaussian parameters. For visualisation and analysis purposes the 
calculated dual counts are often randomised to a gaussian or uniform distribution and 
assigned new values.  
2.1.2 Sample Preparation 
To label desired targets a staining procedure must be performed. Often several are needed to 
label all targets. Tagging of specific proteins can be done by conjugating antibodies that will 
bind the target proteins[52-54]. Nucleic acids can be tagged by using rhodium or iridium 
chelated intercalators [55]. Lipids can also be stained by using osmium or ruthenium 
tetroxide[56] and DNA synthesis can be measured by adding 5‐iodo‐2‐deoxyuridine to the cell 




Proteins can also be stained non-specifically by using nonspecific tags such as cisplatin or 
isothiocyanobenzyl-EDTA chelated with different isotopes of palladium [60-62].  
2.1.2.1 Live Dead Staining 
To differentiate between live and dead cells we use the fact that the membrane of dead cells 
is more permeable. By using non-specific markers dead cells can be labelled and later excluded 
from analysis. Typical live dead markers are cisplatin and the intercalators mentioned 
above[55, 62]. Both of these markers stain dead cells strongly, but they might also stain live 
cells to a lesser degree. This applies especially if the cells tend to have a high turnover of 
pinocytosis (common in tumour cells) and the staining is performed over an extended period. 
2.1.2.2 Barcoding 
To ensure equal staining conditions among different samples a barcoding procedure can be 
performed. This also allows collection of data from multiple samples simultaneously. The 
barcoding procedure entails staining each sample with a specific pattern of mass tags before 
combining the samples together for simultaneous antibody staining. The most common 
procedure for barcoding is by the use of palladium tags, however, other tags, such as CD45 
conjugated antibodies, can also be used [63]. A common staining scheme used during 
barcoding is the doublet filtering scheme Zunder et al [61] illustrated in Figure 2.5.  
 
























Figure 2.5: Doublet filtering scheme. Each sample is uniquely stained with a combination of three different palladium isotopes. 
With this scheme doublets of different samples are easily filtered away since the event would be positive for more than three 
isotopes.  
This scheme allows for easy detection of doublets or aggregates from separate samples, since 
they would be positive for more than three isotopes. Doublets of the same sample can still 
occur and would need to be gated out separately. If it’s desired to stain even more samples at 
once, the scheme can be expanded to allow all permutations, but it is important to note that 
this entails some drawbacks. Using all permutations negates doublet filtering and if the 
samples are not washed thoroughly before mixing, remnant staining solution can stain the 
wrong sample and lead to wrongful debarcoding during pre-gating. 
2.1.2.3 Antibody Conjugation 
Before staining with antibodies, they must be tagged with metal isotopes. Several procedures 
exist, but the most common one is to use the MAXPAR polymer from Fluidigm. Other 
procedures may use cadmium nanoparticles, cisplatin, and palladium or indium chelated to 
monomers of DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) or DTPA 
(polymeric pentetic acid) [64]. The MAXPAR polymer, DOTA, and DTPA all have chelation sites 
that bind heavy metals strongly. After having bound metals to the polymer or monomer, 
hereafter referred to as polymer, the polymer can be conjugated to antibodies. Antibodies 
have several functional groups that can be used for conjugation, but only conjugation kits 
using disulphide bridges (see Figure 2.6) are offered by Fluidigm as of November,2018.  
By reducing antibodies with TCEP, disulphide bridges are converted to thiols, which readily 
react with the maleimide group on the polymers. During reduction, the antibodies are partially 
denatured. The denaturing is crucial to successful conjugation, but if the antibodies are overly 
denatured they might become unusable. Each antibody should therefore be tested after 
conjugation. The thiol-maleimide reaction creates a covalent bond, effectively bonding the 
metal loaded polymers to the antibody. This method has been proven effective on IgG isotype 
antibodies without changing the antibody specificity [54]. However, due to differences in 
locations of disulphide bonds among the isotypes other isotypes may not work. The IgM 
isotype for example is not recommended when using this procedure. After the conjugation, 





Figure 2.6: General antibody structure. The structure of a human IgG2-B antibody. Heavy chains of the antibody are coloured 
blue and light chains are coloured green. During reduction of the antibody using TCEP, disulphide bridges are reduced to thiols. 
The thiols can bind maleimide. By using polymers with maleimide groups, reduced antibodies can be conjugated to the 
polymers. If the antibodies are overly reduced it can result in a loss of function. The antibodies bind one antigen in each of the 
two upper edges. Adapted from [65] 
2.1.2.4 DNA Staining 
The last part of sample preparation is usually to stain the DNA. The DNA stain is used to 
differentiate cells from beads (for normalisation) and debris. This is often done using one of 
the intercalators mentioned in section 2.1.2 along with formaldehyde and a permeabilization 
solution. The formaldehyde is important for preventing cell loss during water washes and data 
collection.  
2.1.2.5 Water Washes 
The last part of the sample prep is washing the sample in pure Milli-Q grade water. This is to 
reduce build-up of salts in the machine and in the nebuliser. Salt build up can cause clogs and 
lead to ion transmission loss due to accumulation on the cones. The water washes are, 
however, damaging for the cells. The hypotonic solution leads to cell disintegration and can 
create puzzling artefacts. Proper fixation is therefore vital. Recently Fluidigm has released a 




cell acquisition solution (CAS). To use this solution however, the injector that transfers cells 
from the heating chamber to the plasma must be switched with one having a wider bore. 
2.1.3 Flow Cytometry as an Alternative 
Most current studies use flow cytometry to study immune cell populations. While flow 
cytometry can analyse tens of thousands of cells per second, it is often limited to only ten 
simultaneous measurements [46]. In research laboratories the use of 17 fluorescent labels in 
flow cytometry has been utilised, but it demands extensive customisation [66]. Mass 
cytometry has a disadvantage in terms of cell throughput, reaching a theoretical maximum at 
3000 cells per second [46]. The advantage is, however, the potential of measuring 135 
different isotope tags, as the mass cytometer has a mass range covering 75 through 209 
daltons [44]. This high dimensional single cell analysis can allow for characterisation of never 
seen before cell types. A comparison of mass cytometry and flow cytometry is summarised in 
Table 2.1. 
Table 2.1: Comparison of flow cytometry and mass cytometry. 
 Flow cytometry Mass cytometry 
Throughput >10,000 cells/s >3,000 cells/s 
Number of parameters Typically, 8+2 (physical) 47 commercially available  
Physical parameters Forward scatter and side 
scatter 
Osmium tetroxide can be used 
as surrogate marker for 
forward scatter.  
Background Significant spectral overlap 
with increased number of 
markers.  
Abundance sensitivity (>0.3%), 
oxide formation (>3%), and 
isotopic impurity (<2%)  
Cell endpoints Cell can be kept alive and 
sorted after analysis. 
Cells are incinerated during 
analysis. 
Autofluorescence Significant autofluorescence Minimal autofluorescence 






2.2 Data analysis 
The data analysis is generally divided into two parts; the pre-gating and the high dimensional 
analyses. During pre-gating machine dependent sensitivity decline is corrected for and 
barcoded samples are debarcoded. 
2.2.1 Normalisation 
During running, loss of detector sensitivity leads to a decline in registered signal intensity. This 
means that two identical cells with identical staining will yield two different signal intensities 
depending on when they were run. To correct for the decline, beads are mixed with the 
sample before acquisition. The beads contain a mix of different heavy metal covering a part 
of the mass spectrum registered by the machine and are highly similar to each other. By using 
these beads, the decline in sensitivity can be corrected for using normalisation procedures. In 
addition, cleaning of the instrument can affect ion throughput, and thus the intensity 
registered. This again means that identical samples run on separate days can yield different 
results. By using the beads as a reference however, the difference can be normalised. Two 
procedures exist for normalisation and differ in the reference used during normalisation. The 
Fluidigm method uses a lot specific dual count mean from the bead production to correct for 
the differences across different runs on different machines (of the same model). The MATLAB 
method, however, uses the median intensity across the samples as a reference [67]. This 
means that the samples have to be normalised as a group for them to be comparable, as 
opposed to the Fluidigm method where they can be normalised one by one [68].  
The sample acquisitions are often interrupted. Since each run gives one file, the same sample 
can end up being in spread over multiple different files. To make data handling more 
manageable the files are typically concatenated after normalisation.  
2.2.2 Debarcoding 
If several samples were barcoded as previously described and combined before staining, it is 
necessary to debarcode them again to extract the individual samples. This is done by 
stratifying the events based on the three barcoding isotopes with highest intensity. The 
barcode intensities are normalised so the highest in the sample gets a value of 1 and the 




normalisation are then used as a threshold to remove doublet and debris. A Mahalanobis 
distance threshold can also be applied to remove outliers.  
It is important to note that the barcode staining intensity is highly dependent on the cell 
number during staining and cell type [61]. This means adjusting the barcode separation or 
applying a minimum intensity threshold can select for specific samples or cell types. 
2.2.3 Gating 
To filter out singlets of the sample a combination of event length and intercalator intensity is 
typically used. A drawback using the intensity of intercalator is however that different cell 
types stain differently [69]. Thus, using this as a primary gate could potentially be biasing the 
data. As mentioned in the last paragraph of section 2.1.1.5, the gaussian parameters can be 
used to identify singlets. Several types of doublets exist. The doublets can be caused by a single 
cell cloud overlapping with debris or another single cell cloud or by cells sticking to each other 
due to poor mixing during fixation. If the clouds are overlapping the singlet filtering can be 
based on the gaussian parameters alone (see Figure 2.7). However, if cells are sticking to each 
other, the intercalator, or another marker, must be used in addition. It is therefore best to use 
all of the mentioned parameters. 
 
 
Figure 2.7: Three different types of doublets due to overlapping clouds. The doublets affect the gaussian parameters, making 
them easy to identify. All doublets yield a high residual due to the non-gaussian shape and a high event length. A: The high 
second peak gives a high centre and a low width. B: The high first peak gives a low centre and a low width. C: The centre and 
width values can vary. Reproduced from [69]. 
2.2.4 Dimensionality Reduction 
In mass cytometry over 30 different parameters can be measured per single cell. Due to the 
high dimensionality of the data, creating a 2D projection showing all differences between each 




known as t-distributed stochastic neighbour embedding (tSNE) [70], similar cells can be placed 
close to each other in an iterative process where short distances in the high dimensional space 
cause an attractive force between the cells and long distances in the high dimensional space 
cause a repelling force. To calculate the similarity between the 2-dimensional space and the 
high-dimensional one a Kullback-Leibler (KL) divergence is calculated and used as a cost 
function. The gradient of the cost function is calculated to know how to move each cell to 
reduce the KL divergence [71]. The KL divergence is a useful tool to determine if enough 
iterations have been performed on the tSNE. 
2.2.5 Clustering 
Traditionally cells have been divided into separate cell types. Since all cells originate from the 
same embryo, however, every cell type must have an intermediate. This leads to a 
fundamental problem: how do you decide where the line separating two cell types is? 
Traditionally, samples have been gated using subjective knowledge and established norms, 
but with the increase of measured parameters the traditional gating procedure can become 
very laborious. If 30 parameters are measured, a total of 
30∗29
2
= 435 unique scatter plots can 
be made. All of the scatterplots might not make sense to analyse given prior knowledge. But, 
using only prior knowledge can lead to loss of cell phenotype discovery. Automatic clustering 
algorithms therefore represent a way to cluster a sample fast and less biased. In addition, high 
dimensional clustering algorithms are not restricted to analysing only two parameters at a 
time when deciding cluster.  
Phenograph [72] is a common clustering algorithm  applied to mass cytometry data. Briefly, 
the algorithm works by creating a network connecting each cell to its k (a user chosen value) 
nearest neighbours and then weights each connection by the calculating the number of shared 
neighbours for each cell-cell pair. Communities (i.e. clusters) are then found by applying an 
approximation, known as the Louvain Method, on the weighted network. This approximation 
gradually assigns cells to communities based on the increase of modularity (an estimate of 
network density in a community). The Louvain Method is run several times and the 




2.2.6 Cluster Characterisation 
Since the clustering algorithm often finds several clusters, an easy way of characterising each 
cluster is needed. Marker Enrichment Modelling is a useful tool developed by Diggins et. al 
[73] and works by calculating a MEM-value for each marker in each cluster.  
The equation used is: 
𝑀𝐸𝑀 = |𝑚𝑒𝑑𝑖𝑎𝑛𝑐𝑙𝑢𝑠𝑡𝑒𝑟 − 𝑚𝑒𝑑𝑖𝑎𝑛𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒| + (
𝐼𝑄𝑅𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒
𝐼𝑄𝑅𝑐𝑙𝑢𝑠𝑡𝑒𝑟
) − 1 
𝑖𝑓 (𝑚𝑒𝑑𝑖𝑎𝑛𝑐𝑙𝑢𝑠𝑡𝑒𝑟 < 𝑚𝑒𝑑𝑖𝑎𝑛𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒): 𝑀𝐸𝑀 =  −𝑀𝐸𝑀 
Thus, if there is a large difference between the median of the cluster and the population, or if 
the interquartile range (IQR) is smaller in the cluster than in the reference, then the MEM-
value increases.  
The reference used is often the rest of the clusters, but a selected reference sample can also 
be used.  
2.3 Reasons for the Approach 
The immune system is complex and consists of several different phenotypes, each serving 
specific functions. To determine how the immune system is affected by tumour development 
and therapy, the immune landscape must be mapped and compared across timepoints and 
treatments. Since the cell phenotype is determined by protein expression, it is vital to detect 
these proteins. Mass cytometry allows measuring of over 40 tags simultaneously on single 
cells and is commercially available. Thus, this method is fit to determine cell phenotypes in 
heterogenous single cell samples. The high dimensional data would earlier be a problem, but 
due to recent developments in data processing and machine learning the data can be analysed 
unbiased and efficiently. An alternative to mass cytometry is flow cytometry. However, flow 
cytometry is limited by the number of tags that can be used simultaneously and the significant 





3 Materials and Methods 
3.1 General Overview 
The methods can be divided into four parts as depicted in Figure 1.7. The first part entails 
tumour injection, treatment and tissue harvesting. The second part continues with tissue 
treatment and its treatment until being run on the mass cytometer. The data acquisition has 
gotten its own section to separate it from the analysis and the sample preparation. Lastly, the 
data analysis is explained, starting with normalisation and ending with calculation of statistics 
from cell clusters. Animals, chemicals, antibodies, and equipment 
Table 3.1: Materials used for cell culturing, mouse treatment, and tissue dissociation. 
Description Source Product number Details 
4T1  ATCC 
 
CRL-2539 
Anti-mCTLA-4 BioXCell BE0131 Syrian Hamster 
IgG, clone 9H10 
Anti-mPD-1  BioXCell BE0146 rat IgG2a, clone 
RMP1-14 






Cisplatin-194 Fluidigm 201194 5mM stock 
C-tubes Miltenyi Biotec 130-096-334 
 
Fetal bovine serum Sigma F7524 
 
gentleMACS Dissociator Miltenyi Biotec 130-093-235 
 
L-Glutamine solution Sigma G7513-100ML  
MACS SmartStrainers (70 
µm) 
Miltenyi Biotec 130-110-916 
 
MACS Tissue Storage 
Solution 
Miltenyi Biotec 130-100-008 
 
Matrigel Basement 




Penecillin-Streptomycin Sigma P0781-100ML  
Polyclonal Armenian 
Hamster IgG 
BioXCell BE0091 BE0091  
Pre-Separation Filters (30 
µm) 
Miltenyi Biotec 130-041-407 
 
Red Blood Cell Lysis 
Solution (10×) 
Miltenyi Biotec 130-094-183 
 
RPMI -1640 Medium Sigma R8758-500ML 
 
Spleen Dissociation Kit, 
mouse 





Sterile Cell Strainner 40 µm Fischer 
Scientific 
22363547  
Trypsin - EDTA Solution Sigma T4047-100ML  
Tumor Dissociation Kit, 
mouse 
Miltenyi Biotec 130-096-730 
 
 
Table 3.2: Materials needed for antibody conjugation. 
Description Source Product numbe Lot number  
Antibody stabilizer CANDOR 131 050 131D324v 
C-buffer Fluidigm S00004 0071601 
L-buffer Fluidigm S00008 2781505 




W-buffer Fluidigm S00006 2751520 






Lanthanide solutions Fluidigm   
Centrifugal Filter Unit: 3 
kDa Amicon Ultra 500 µL V 
bottom 
Millipore UFC500396  
Centrifugal Filter Unit: 50 
kDa Amicon Ultra 500 µL V 
bottom 
Millipore UFC505096  
 
Table 3.3: Chemicals used during sample preparation. 
Description Source Product number Lot 
number  
Antibody stabilizer CANDOR 131 050 131D324v 
Barcode perm (10x) Fluidigm 201057 1381803 
Barcodes Fluidigm S00114 2461603 
Bovine serum albumin 
(BSA) 
Sigma Aldrich A9647-100G SLBV4996 
C-buffer Fluidigm S00004 0071601 
Cell staining buffer Fluidigm 201068 3001610 
DNase I Sigma Aldrich DN25-1G SLBV1446 
Dulbecco's phosphate 
buffered saline (DPBS) 
Gibco 14040-133 1941466 
EDTA Sigma Aldrich E5134-250G BCBV7014 













Phosphate buffered saline 
(PBS) 
Sigma Aldrich P4417-100TAB SLBW3999 
Sodium azide Merck 106688  
Syringe 30 ml BD Plastipak   
Tube 15 ml  Sarstedt 62.554.502  
Tube 5 ml  Sarstedt 55.1578  
Tube 50 ml Sarstedt 62.547.254  
 
Table 3.4: List of mass cytometry panel and antibodies used for staining. *Antibodies used during intracellular staining. 
†Antibodies used during surface staining. All antibodies from companies other than Fluidigm were conjugated to the given 
mass tag. Superscripted numbers indicate backbone number. 
Product Mass tag Clone Source Product number Lot 
Intercalator 
(Rh) 
103Rh None Fluidigm 201103A 1801702 
CD11c†1 142Nd N418 Fluidigm 3142003B 2431705 
CD69†3 143Nd H1.2F3 Fluidigm 3143004B 1171706 
CD115†2 144Nd AFS98 Fluidigm 3144012B 1111704 
CD4†2 145Nd RM4-5 Fluidigm 3145002B 0901505 
CD8a†2 146Nd 53-6.7 Fluidigm 3146003B 0351301 
CD45†1 147Sm 30-F11 Fluidigm 3147003B 0901705 
PD-1 
(CD279)† 2 
148Nd RMP1-30 eBiosciences 14-9981-82 4311070 
CD83†3 149Sm Michel-17 eBiosciences 14-0831-82 4274058 
CD24†3 150Nd M1/69 Fluidigm 3150009B 0901508 
CD64†1 151Eu X54-5/7.1 Fluidigm 3151012B 2601611 
CD3e†1 152Sm 145-2C11 Fluidigm 3152004B 3181714 
PD-L1 
(CD274)† 1 
153Eu 10F.9G2 Fluidigm 3153016B 1711724 
CD11b†1 154Sm M1/70 Fluidigm 3154006B 2341710 
CD114†2 155Gd 723806 R&D MAB60391 CFZR01170
71 
CD103†3 156Gd 2E7 eBiosciences 14-1031-85 4318103 
FOXP3*3 158Gd FJK-16s Fluidigm 3158003A 3461707 
FOXP3*3 158Gd FJK-16s Fluidigm 3158003A 1841813 
F4/80†2 159Tb BM8 Fluidigm 3159009B 0541707 
ARGINASE 
1*3 
160Gd Polyclonal Novus 
Biologicals 
NBP1-32731 42893 
iNOS*3 161Dy CXNFT Fluidigm 3161011B 1171714 
Ly-6C†2 162Dy HK1.4 Fluidigm 3162014B 2341706 
CD40†3 163Dy 1C10 R&D MAB440 AHY171707
1 
CD49b†1 164Dy HMα2 Fluidigm 3164011B 1531401 
CD25†3 165Ho 280406 R&D MAB2438 VDI011302
1 






167Er 29A1.4 Fluidigm 3167008B 3131704 
CTLA-4 
(CD152) †2 
168Er UC10-4B9 invitrogen 14-1522-82 1953873 
CD206†3 169Tm C068C2 Fluidigm 3169021B 1881729 
MER†1 170Er 2B10C42 BioLegend 151502 13233030 
CD80†3 171Yb 16-10A1 Fluidigm 3171008B 3001404 








174Yb RB6-8C5 Fluidigm 3174008B 3181408 
AXL†3 176Yb MAB854 R&D MAB854 JMT021806
1 




191/193Ir None Fluidigm 201192B 2301702 
Cisplatin 194Pt None Fluidigm 201194  
I-A/I-E†2 209Bi3 M5/114.1
5.2 
Fluidigm 3209006B 2851707 
CD16/32*† None 93 eBiosciences 16-0161-85 4316711 
 
3.1.1 Preparation of stock solutions 
3.1.1.1 Cell Culture Medium 
50 ml FBS, 5 ml L-glutamine, and 5 ml Penicillin-Streptomycin was diluted in 500 ml RPMI1640 
in a sterile laminar airflow hood. The cell medium was stored at 4°C. 
3.1.1.2 100x DNase I 
10 ml DPBS was transferred to a 15 ml tube. 250 mg DNase I was transferred to the tube and 
dissolved. The 10 ml were aliquoted to and stored at -20°C. 
3.1.1.3 10x PBS 
2 PBS-tablets were dissolved in 40 ml MilliQ in a 50 ml tube. The solution was stored at 4 °C. 
3.1.1.4 10x PBS (20 mM EDTA) 
2 PBS-tablets and 297.8 mg EDTA was dissolved in 40 ml MilliQ in a 50 ml tube. The solution 




3.1.1.5 25x stock sodium azide (NaAz) 
250 mg sodium azide was diluted in 50 ml MilliQ in a 50 ml tube and stored at 4°C. 
3.1.1.6 Cell Washing Buffer (CWB) 
5 g BSA, 48 ml DPBS, and 2 ml 25x NaAz was transferred to a 50 ml tube. After the BSA had 
dissolved the solution was passed through a 2 µm filter using a 30 ml syringe and stored at 
4°C. At the day of use, thawed 100x DNase I was added in the ratio of 1:99. 
3.1.1.1 2% PFA 
1 ml 10x PBS (20mM EDTA) and 1.25 ml 16% PFA were diluted in 7.75 ml MilliQ in a 50 ml 
tube. The solution was passed through a 2 µm filter using a 30 ml syringe. 
3.2 Mice 
The following mouse experiment was approved by the Norwegian Food Safety Authority 
(Mattilsynet) and performed in accordance with Regulation on the use of animals in research. 
Mice were checked every 2-3 days before treatment start and daily thereafter.  
BALB/c mice (n=50) were implanted with 4T1 breast cancer cells and treated with a control, 
bemcentinib, anti-CTLA-4 and anti-PD-1 (ICB), or a combination of bemcentinib and ICB. 40 of 
the 50 animals were divided into 8 equal sized groups by treatment and treatment duration. 
The 10 extra animals were needed to ensure the 8 groups were in similar stages of tumour 
growth, i.e. that the tumour volumes were similar, to be used as test samples for titration of 
antibodies, and to make a control sample to compare results across mass cytometry runs. Each 
cage contained 5 animals and was assigned a letter and a number based on treatment and 
treatment duration, as shown in Table 3.5. The extra animals were placed in cages E1 and E2. 
A timeline for the treatments and euthanasia is shown in Figure 3.1.  
Table 3.5: Treatment and day of euthanasia for the different groups. Tissues were harvested immediately after euthanasia. 
Each group contains 5 animals. 
Group Oral gavage Intraperitoneal 
injection 
Euthanasia 
A1 Vehicle IgG Day 15 
A2 Vehicle IgG Day 22 




B2 Bemcentinib IgG Day 22 
C1 Vehicle Anti CTLA-4 and 
anti PD-1 
Day 15 
C2 Vehicle Anti CTLA-4 and 
anti PD-1 
Day 22 
D1 Bemcentinib Anti CTLA-4 and 
anti PD-1 
Day 15 
D2 Bemcentinib Anti CTLA-4 and 
anti PD-1 
Day 22 
E1 Vehicle IgG Day 15 
E2 Vehicle IgG Day 22 
 
 
Figure 3.1: Timeline for mouse experiment. Five groups were sacrificed 15 days after implantation (2 days of treatment) and 
five groups were sacrificed 22 days after implantation (10 days of treatment). Bem denotes treatment with bemcentinib and 
ICB (immune checkpoint blockade) denotes a combined treatment of anti-PD-1 and anti-CTLA-4. No treatments were given to 
the animals on the day they were euthanised. 
3.2.1 Cell Culture 
Cells were always treated in a sterile laminar airflow hood with gloves and personal lab coat. 
1 million 4T1 BALB/c breast cancer cells were seeded in a T75 flask (75 cm2) and cultured in 
medium (10 ml, as made in 3.1.1.1) in an incubator (37°C, 5% CO2, 21% O2). Upon reaching 80-
90% confluency, the cells were split into 2 T175 flasks with cell medium each containing 20 ml 
cell culture medium. 
After reaching a final confluency of 80-90% in both flasks, medium was aspirated, and cells 
























for cell detachment, after which, medium (10ml) was added for quenching. The cells were 
then transferred to a 15 ml tube and centrifuged (290 g, 7 min, RT). Supernatant was aspirated, 
and the cells were resuspended in new medium and counted using the Countess Cell Counter. 
Medium was then discarded until only 12 million cells remained (200,000 cells per injection, 
thus 12 million cells equates to 60 injections). The cells were again centrifuged (290 g, 7 min, 
RT) and aspirated.  
Cold serum-free RPMI1640 (2 ml) was mixed with Matrigel in a ratio of 1:1. The cells were 
resuspended in RPMI1640-Matrigel mix (3 ml) to a concentration of 4 million cells per ml. 1 
ml syringes were drawn up with 0.3 ml each and left on ice until tumour implantation. 
3.2.2 Tumour Implantation 
Each animal was anaesthetised by Sevoflurane and after reaching sufficient unconsciousness, 
the mice were weighed and placed back in anaesthesia in a cuff and shaved. To remove 
residual hair, Veet Hair Removal Cream was applied to the shaven area and swiftly removed 
with a wet tissue paper RPMI1640-Matrigel mix (0.05 ml, 200,000 cells) was injected into the 
fourth mammary fat pad on right side of the mouse using a 1 ml syringe with a 30-gauge 
needle. 
3.2.3 Preparation of Treatments 
Vehicle (water with 0.1% w/w TWEEN 80 and 0.5% w/w hydroxypropyl methylcellulose) was 
prepared by BerGenBio. To make the stock bemcentinib solution, vehicle was mixed with 
bemcentinib powder (10 mg/ml), vortexed, and sonicated for 15 min. The stock was then 
diluted with vehicle (5 mg/ml) to a dosing suspension. The same dose volume of bemcentinib 
was used for the vehicle-only treatments. 
The anti-mCTLA-4 and anti-mPD-1, comprising the Immune therapy blockade (ICB), were 
individually diluted with sterile PBS to a concentration of 2 mg/ml. A dose of 10 mg/kg was 
used for each mouse. For the control antibody, hamster IgG, a lower dose and a higher 
concentration was used to equalise the volume and amount of antibodies injected with the 
ICB treatment. The treatments with doses and volumes are summarized in Table 3.6. 










Bemcentinib 50 5 10 
Anti-mCTLA-4 10 2 5 
Anti-mPD-1 10 2 5 
Hamster IgG 20 1 10 
Vehicle NA NA 10 
 
Injection volumes were calculated as follows: 




𝑉 is volume to be injected, 𝑊 is the weight of the mouse, 𝐶𝑑𝑜𝑠𝑒 is the concentration of the 
dose [mg/kg], and 𝐶𝑑𝑟𝑢𝑔 is the concentration of the drug [mg/ml].  
Below, a case of for mouse of 25 grams treated with bemcentinib is exemplified: 







= 0.250 𝑚𝑙 
Thus, a total volume of 250 µl is to be injected by oral gavage.  
3.2.4 Randomisation and Treatments 
After the mice had developed tumours with volumes1 ranging from 50 mm3 to 100 mm3 and 
aged beyond 8 weeks, they were randomised into ten cages (5 mice per cage) consisting of 
five treatment groups and two endpoints, by sorting by weight and using Latin Square design. 
At the day of randomisation, treatment was also initiated.  
                                                     
 
 
1 The tumour volume is calculated using the formula 𝑉 =
𝑎∗𝑏2
2
 𝑚𝑚3, where a and b are the long and short 




Bemcentinib and ICB were prepared as stated in section 3.2.3. Prior to each injection the 
weight of the mouse was recorded and used to calculate injection volume, as stated also in 
section 3.2.3. The treatments for the groups are displayed in Table 3.5. 
ICB treatment was given intraperitoneally every other day while bemcentinib and vehicle was 
given by oral gavage twice a day.  
3.2.5 Tissue Collection 
Mice were euthanised at two different timepoints as shown in Table 3.5 and Figure 3.1. The 
mice were first anesthetized with Sevoflurane before being euthanised with cardiac puncture 
followed by cervical dislocation. After euthanasia, tumour and spleen tissue was collected and 
temporarily stored on ice in a 15ml tube with MACS Tissue Storage Solution. 
3.3 Sample Preparation 
Samples were provided as written in section 3.2.5. Sample preparation has been divided into 
two parts: tissue dissociation to make single cell suspensions and the treatment of the single 
cells until running them on the mass cytometer.  
All centrifugation steps were completed on a Centrifuge 5810 R (Eppendorf) with a Swing-
Bucket rotor. 
3.3.1 Tissue Dissociation 
3.3.1.1 Tumour Dissociation  
For tumour tissue dissociation the Tumor Dissociation Kit, mouse (Miltenyi) was used along 
with the supplied protocol. Briefly, for each tumour, a digestion enzyme mix was made by 
mixing RPMI1640 (2350 µl), Enzyme D (100 µl), Enzyme R (50 µl) and Enzyme A (12.5 µl) in a 
C-tube. The tumour was cut in small pieces, transferred to the C-tube and run on the 
gentleMACS Dissociator (Miltenyi) with the m_impTumor_02 program before being incubated 
on a tumble wheel in an incubator (40 min, 37°C). The C-tube was again run on the dissociator 
with the program m_impTumor_03 twice, followed by m_impTumor_01 once. The sample 
was then strained through a 70 µm filter on a 50 ml tube. The filter was washed with RPMI1640 
(10 ml) before again straining the sample through a 40 µm filter into the same tube. The filter 
was washed with RPMI1640 (10 ml). The sample was then centrifuged (200 g, 7 min, RT) and 




ml) and centrifuged (200 g, 7 min, RT). Supernatant was again aspirated, and the cells were 
resuspended in PBS (500 µl) and 1x RBCL (5 ml), made from Red Blood Cell Lysis Solution (10×) 
diluted in MilliQ, and incubated (2 min, RT). The sample was centrifuged (200g, 10 min, RT) 
and supernatant aspirated.  
3.3.1.2 Spleen Dissociation 
For spleen tissue dissociation the Spleen Dissociation Kit, mouse (Miltenyi) was used along 
with the supplied protocol. Briefly, for each spleen, a digestion enzyme mix was made by 
mixing Buffer S (2.4 ml), Enzyme D (50 µl), and Enzyme A (15 µl) in a C-tube. The spleen was 
transferred whole to the C-tube and run on the gentleMACS Dissociator (Miltenyi) with the 
m_spleen_02 program before being incubated in a tumble wheel for 15 min at 37°C. The C-
tube was then run on the dissociator with the program m_spleen_03, before being strained 
through a 30 µm filter on a 15 ml tube. The filter is washed with 1x Buffer S (2.5 ml). The 
sample was then centrifuged (200 g, 10 min, RT) and supernatant was aspirated. The cells 
were resuspended in PBS (500 µl) and 1x RBCL (5 ml), made from Red Blood Cell Lysis Solution 
(10×) diluted in MilliQ, and incubated (2 min, RT). The sample was centrifuged (200g, 10 min, 
RT) and supernatant aspirated. 
3.3.1.3 Live Dead Staining 
After having prepared the samples as stated in section 3.3.1, the cells were resuspended in 
RPMI1640 (5 ml, 10% FBS, 0.25 µM cisplatin) and mixed by inverting the tube. The sample was 
incubated (5 min, RT) before being quenched by the addition of RPMI1640 (5ml, 10% FBS). 
The sample was then centrifuged (200 g, 6 min, RT). Supernatant was aspirated, and cells 
transferred to a Cryotube (1.8 ml) with RPMI1640 (900 µl). The sample was fixed for 10 min 
by the addition of PFA (100µl, 16%) before centrifugation (900 g, 5 min, RT). Supernatant was 
aspirated, and the tube frozen to -80°C. 
3.3.2 Antibody Conjugation and Titration 
3.3.2.1 Antibody Conjugation 
Antibody conjugation was performed using Maxpar Antibody Labeling Kit, containing all the 
necessary solutions except TCEP and Antibody stabiliser, with the supplied protocol. Briefly, 
the MAXPAR polymer was thawed and mixed with L-buffer (95 µl) and lanthanide ion solution 




concentration of the antibody to be conjugated was measured on a NanoDrop (2000/2000c , 
Thermo Scientific). A calculated volume (100 µg antibody) was transferred to the 50 kDa filter 
with additional R-buffer to get a total volume of 0.5 ml and centrifuged (12 000 g, 10 min, RT). 
A TCEP-R-buffer solution was prepared by diluting TCEP (8 µl, 0.5 M) in R-buffer (992 µl). Flow 
through from the antibody centrifugation was discarded and the antibody was resuspended 
in TCEP-R-buffer (100 µl) and incubated in a heating block (30 min, 37 °C). The lanthanide 
polymer was transferred to the 3 kDa filter and diluted in additional L-buffer (200 µl) and 
centrifuged (12 000 g, 25 min, RT). Flow through was discarded and the polymer was washed 
again in C-buffer (400 µl) and centrifuged (12 000 g, 30 min, RT). C- buffer (300 µl) was added 
to the 50 kDa filter with the antibody before the antibody was centrifuged (12 000 g, 10 min, 
RT). The flow through from the antibodies was discarded and the wash repeated with C-buffer 
(400 µl) and centrifugation (12 000 g, 10 min, RT). The flow through from both the polymer 
and the antibodies was discarded.  
C-buffer (60 µl) was added to the 5 kDa filter with the polymer and used to transfer the 
polymer to the 50 kDa filter containing the antibodies. The 50 kDa filter now containing both 
the polymers and the antibodies was placed in a heating block (90 min, 37 °C).  
W-buffer (200 µl) was added to the 50 kDa filter before being centrifuged (12 000 g, 10 min). 
Flow through was discarded and the wash repeated three times, for a total of four, with W-
buffer (400 µl). After discarding the flow through, the antibody concentration was measured 
on the Nanodrop. The measured concentration was used to calculate the volume of Antibody 
Stabilizer needed for diluting the antibody to 0.5 mg/ml. The 50 kDa filter was centrifuged (12 
000 g, 10 min, RT) and the calculated volume of Antibody Stabilizer was added to the filter. 
The filter was then transferred to a new tube and placed upside down for collection of the 
antibody during centrifugation (1 000 g, 2 min, RT). The conjugated antibody was then stored 
at 4 °C in the dark. 
3.3.2.2 Antibody Titration 
The complete antibody panel was divided into three backbones (see Table 3.4), so that the 
canonical markers were titrated first, and markers on subpopulations of the canonical markers 
were titrated next. For each backbone, about 3 million cells from a spleen sample was divided 
into six tubes and barcoded. The samples were then stained with a serial dilution of the 




were then combined in a tube. The samples were run on the mass cytometer and, ±1 spill, +16 
spill, and separation between positive and negative populations were analysed and used to 
determine the best titration for each antibody.  
3.3.3 Cell Staining  
Each sample was divided into 6 groups as shown in Table 3.7. Each of the groups contains 20 
samples and was stained and run at the mass cytometer at the same time. The extra test 
samples from the E-group were used for titrating antibodies and making a control spleen 
sample to be included in every run. 
Table 3.7: All single cell suspension samples from section 3.3.1.3 were divided into five groups based on tissue, treatment 
group and treatment duration. Each cell designates an animal characterised by the treatment group (first letter), the 
treatment duration (first number before the dash) and mouse number in the given cage (the last number).  




A1-1 A2-1 A1-1 A2-1 E1-1 E1-1 
A1-2 A2-2 A1-2 A2-2 E1-2 E1-2 
A1-3 A2-3 A1-3 A2-3 E1-3 E1-3 
A1-4 A2-4 A1-4 A2-4 E1-4 E1-4 
A1-5 A2-5 A1-5 A2-5 E1-5 E1-5 
B1-1 B2-1 B1-1 B2-1 E2-1 E2-1 
B1-2 B2-2 B1-2 B2-2 E2-2 E2-2 
B1-3 B2-3 B1-3 B2-3 E2-3 E2-3 
B1-4 B2-4 B1-4 B2-4 E2-4 E2-4 
B1-5 B2-5 B1-5 B2-5 E2-5 E2-5 
C1-1 C2-1 C1-1 C2-1 
  
C1-2 C2-2 C1-2 C2-2 
  
C1-3 C2-3 C1-3 C2-3 
  
C1-4 C2-4 C1-4 C2-4 
  
C1-5 C2-5 C1-5 C2-5 
  
D1-1 D2-1 D1-1 D2-1 
  
D1-2 D2-2 D1-2 D2-2 
  
D1-3 D2-3 D1-3 D2-3 
  
D1-4 D2-4 D1-4 D2-4 
  
D1-5 D2-5 D1-5 D2-5 
  
Control Control Control Control   
 
3.3.3.1 Barcode Staining 




The samples from section 3.3.1.3 were divided into four groups based on tissue and treatment 
endpoint. A sample control made from a mix of spleen samples from the E-group was included 
in each mass cytometry run. 
Each sample was thawed and resuspended in DPBS (500 µl) with 1x DNase I. A small sample 
of about 10 µl was used the estimate cell count in the tube. Based on the cell count, at least 3 
million cells were transferred to a new 5 ml tube. Additional cell washing buffer (CWB) was 
subsequently added to give a final volume of 1 ml. The sample was then vortexed, centrifuged, 
and subsequently decanted.  
Perm buffer was prepared by diluting 10x perm buffer (5ml, Fluidigm) with 10x PBS (5 ml) and 
Milli-Q (40 ml). The sample was washed with perm buffer (1 ml), centrifuged, and 
subsequently decanted. This washing step was performed twice, except aspirating to remove 
supernatant the second time.  
For the control sample: rhodium intercalator (1µl, 500µM) was mixed with perm buffer 
(200µl). The control sample cells were resuspended in the rhodium intercalator mix and 
incubated (30 min, RT). 
For non-control samples: the samples were put on ice and when ice cold, ice cold perm buffer 
(195 µl) was mixed with barcode solution (5 µl, Fluidigm) and swiftly used to resuspend the 
cells by pipetting. The cells were incubated (30 min, RT).  
After incubation, CWB (800 µl) was transferred to the tubes before being centrifuged and 
subsequently decanted. The cells were resuspended with CWB (1 ml), vortexed and incubated 
(10 min, RT) before being centrifuged and supernatant aspirated. Each sample was 
resuspended in CWB (100 µl) and grouped in a 5 ml tube. CWB (100 µl) was added to each 
sample tube to transfer any remaining cells to the grouped 5 ml tube. The grouped samples 
were centrifuged and subsequently decanted before being washed with CSM (4 ml, Cell 
staining medium). After centrifugation the tube was decanted and put on ice.  
3.3.3.2 Marker Staining 
All centrifugation steps were performed with swing-bucket rotor at 900 g for 5 min in RT., 




Fc-block (anti-CD16/32) was diluted in CSM in a ratio of 1:199. The cells from section 3.3.3.1 
were resuspended in diluted Fc-block (35 µl per 3 million cells) and incubated (10 min, on ice). 
All antibodies (see Table 3.4) were vortexed, centrifuged (10,000 g, 5 min, RT) and put on ice. 
Titrated amounts of each surface antibody (see Table 10.1) were mixed with CSM to give a 
total volume of 40 µl per 3 million cells. The antibody cocktail was mixed with the sample and 
incubated (30 min, RT). After incubation, the sample was centrifuged, aspirated and 
resuspended and incubated in DPBS (4 ml) with 1x DNase I for 10 min. The sample was then 
centrifuged and subsequently resuspended in PBS (4ml, 2 mM EDTA), centrifuged, and 
decanted.  
200 µl 2% PFA per 3 million cells was used to resuspend the sample. The sample was then 
incubated (30 min, RT, in the dark) before being centrifuged (900g, 5 min, RT), and supernatant 
aspirated. The sample was then resuspended in CSM/perm (2ml, 10% 10x perm buffer), 
centrifuged, and decanted. This washing procedure was repeated once for a total of two 
times. Fc-block (anti-CD16/32) was diluted in CSM/perm in a ratio of 1:199. The sampel was 
then resuspended in diluted Fc-block (35 µl per 3 million cells) and incubated (10 min, on ice).  
Titrated amounts of each intracellular antibody (see Table 10.1) were mixed with CSM/perm 
to give a total volume of 40 µl per 3 million cells. The antibody cocktail was mixed with the 
sample and incubated (30 min, RT). After incubation, the sample was centrifuged, aspirated 
and resuspended and incubated in CWB (4 ml, 10 min, RT). The sample was then centrifuged 
and subsequently resuspended in PBS (4ml, 2 mM EDTA), centrifuged, and decanted.  
3.3.3.3 DNA-Staining, Water Washes and Data Aquisition 
Iridium intercalator (0.33 µl per 20,000,000 cells, 500 µM) was mixed with 2% PFA (1 ml per 
20,000,000 cells). The cells were incubated at 4°C overnight. 
The sample was centrifuged (900 g, 5 min, RT), and supernatant was aspirated. CWB (2 ml) 
was used to resuspend the cells. The sample was incubated (10 min, RT) then centrifuged (900 
g, 5 min, RT). The sample was finally resuspended in PBS (2ml, 2 mM EDTA) and put on ice. 
Before running the sample on the mass cytometer, the sample was washed in MilliQ. This was 
done by transferring 200 µl (roughly one million cells) of the sample to a new 5 ml tube and 
filling it with MilliQ (4 ml). The tube was inverted for mixing, centrifuged (400 g, 5 min, RT), 




Finally, the cells were resuspended in about 0.75 ml 1x bead solution to a final concentration 
of about 1-2 million cells per ml, pushed through a 40 µm filter and acquired on the mass 
cytometer. During acquisition a rain plot showing the amount of each isotope detected in each 
push can be studied to identify contaminations (see Figure 3.2). 
 
Figure 3.2: A mass cytometry rainplot. A rain plot showing measured isotopes (columns) in each push (rows). Pushes 
containing cells can be identified by finding the pushes with high amounts of iridium 191 and 193. Some background of 147Sm 
and 209Bi can be identified by comparing the intensity between cells. 
For each timepoint, approximately 10 million events were collected from the spleen samples 
and 14-15 million events from the tumour samples.  
The mass cytometry was performed using the Helios at the Flow Cytometry Core Facility, 
Department of Clinical Science, University of Bergen.  
3.4 Data Analysis 
3.4.1 Pre-gating 
3.4.1.1 Normalisation 
Samples were normalised with the Fluidigm CyTOF software (version 6.7.1014). The median 
bead intensity was used on a sliding window of 200 seconds. After normalisation, the files 
were concatenated and randomised. The values above 0 were randomised using a gaussian 
distribution with a sigma of 1, while zero-values were randomised with a sigma of 1 and a half-
zero randomisation power parameter of -0.5.  
3.4.1.2 Debarcoding 
Normalised events were debarcoded using Fluidigm CyTOF software (version 6.7.1014). The 




cytometry run. The signal intensity cut-off was used for the tumour sample, but not used for 
the spleen samples. A typical debarcoding result is shown in Figure 3.3.  
 
Figure 3.3: Debarcoding yields. Debarcoding of the first tumour run, containing 20 sample and 1 control (unassigned). A 
separation threshold of 0.14 was used in this case for debarcoding. Due to differing amount of cells during barcoding, the 
optimal barcode separation threshold varies across sampels. 
3.4.1.3 Gating 
Before gating, an arcsinh transformation with the argument of 2 was applied on all marker 
channels. The general gating strategy is summarised in Figure 3.4. The process starts with 
removal of 140Ce positive beads and then uses the gaussian parameters to select single ions 
clouds. Live single cloud events are then selected by excluding 194Pt high events. Single 
immune cells are selected by CD45 and based on 103Rh staining the cells are characterised as 





Figure 3.4: Manual gating strategy. Gating strategy to select single immune cells for the samples and the control.  
3.4.2 Clustering and Dimensionality Reduction  
After gating out single immune cells, each file in each mass cytometry run was subsampled 
equally. The spleen samples were randomly subsampled to 20 000 cells per file, and the 
tumour samples were subsampled to 23 809 cells per file. Phenograph clustering was run on 
tissue and timepoints separately with a k=30. The Phenograph algorithm was run on R (version 
3.5.1) using the R implementation of Phenograph [72] and flowCore [74]. Phenograph plots 
were made using cytofkit [75].  
The tSNE algorithm was run separately on each of the four phenograph clustering analyses 
using the viSNE implementation in Cytobank.  
Markers used during clustering and dimensionality reduction are summarised in Table 3.8. 




Table 3.8: Markers used during dimensionality reduction and clustering. FOXP3 was not used due to not staining any T cells. 
Marker Mass tag tSNE Clustering 
Intercalator 
(Rh) 
103Rh No No 
CD11c†1 142Nd Yes Yes 
CD69†3 143Nd Yes Yes 
CD115†2 144Nd Yes Yes 
CD4†2 145Nd Yes Yes 
CD8a†2 146Nd Yes Yes 
CD45†1 147Sm Yes Yes 
PD-1 (CD279)† 
2 
148Nd Yes Yes 
CD83†3 149Sm Yes Yes 
CD24†3 150Nd Yes Yes 
CD64†1 151Eu Yes Yes 
CD3e†1 152Sm Yes Yes 
PD-L1 
(CD274)† 1 
153Eu Yes Yes 
CD11b†1 154Sm Yes Yes 
CD114†2 155Gd Yes Yes 
CD103†3 156Gd Yes Yes 
FOXP3*3 158Gd No No 
FOXP3*3 158Gd No No 
F4/80†2 159Tb Yes Yes 
ARGINASE 1*3 160Gd Yes Yes 
iNOS*3 161Dy Yes Yes 
Ly-6C†2 162Dy Yes Yes 
CD40†3 163Dy Yes Yes 
CD49b†1 164Dy Yes Yes 
CD25†3 165Ho Yes Yes 
CD19†1 166Er Yes Yes 
CD335 
(NKp46) †1 
167Er Yes Yes 
CTLA-4 
(CD152) †2 
168Er Yes Yes 
CD206†3 169Tm Yes Yes 
MER†1 170Er Yes Yes 
CD80†3 171Yb Yes Yes 
CD86†3 172Yb Yes Yes 
CD116 (GM-
CSF R) †2 
173Yb Yes Yes 
Ly-6G/C (Gr-1) 
†2 
174Yb Yes Yes 
AXL†3 176Yb Yes Yes 
AXL†3 176Yb Yes Yes 
Intercalator 
(Ir) 




Cisplatin 194Pt No No 
I-A/I-E†2 209Bi3 Yes Yes 
 
3.4.3 Cluster Characterisation 
To characterise each cluster and make heatplots, the R-package MEM [76] was used, with the 
remaining clusters acting as reference. 
3.4.4 Statistical Analysis 
Each of the four Phenograph clustering analyses were analysed separately by running a two-
way factorial ANOVA, with bemcentinib and ICB as two-level factors, to compare each cluster 
across treatments. The false discovery rate was controlled for each Phenograph analysis at 5% 
using the Benjamini-Hochber method.  
A two-way analysis of variance (ANOVA) was conducted on the influence of two independent 
variables (Bemcentinib treatment, ICB treatment) on the number of cells in each cluster. Both 
bemcentinib and ICB treatment included two levels, (yes, no). The ANOVA was conducted in 
R, using the manova function in “stats” (version 3.5.1) with the formula “clusters ~ 
bemcentinib*ICB”. P-value correction and calculation of means for cluster sizes was 
performed in GraphPad Prism 8.0. Circle diagrams, representing number of cells in each 
cluster, was made using Excel.  
The following analyses were also performed in GraphPad Prism 8.0. Cluster sizes were 
analysed with multiple linear regression against tumour and spleen weight. A three-way 
ANOVA was performed using tumour size across treatments and time as factors. The same 
analysis was also used on spleen size and tumour weight. Spleen weight and tumour weight 
was correlated using linear regression.  
3.4.5 Phenotyping 
The following scheme was used in phenotyping: 
T helper cells  CD3+CD4+ 
Cytotoxic T cells CD3+CD8+ 
B cells CD19+I-A/I-E+ 




Dendritic cells I-A/I-E+CD11c+CD11b- 
Tumour associated macrophage type 1 iNOS+CD11b+ 
Tumour associated macrophage type 2 CD206+CD11b+ 






4 Results  
4.1 Spleen and Tumour Weight 
4.1.1 Tumour Volume 
The study by Davidsen et al. shown in section 1.3.3 analysing the combination of ICB and 
bemcentinib used tumour volume of as endpoint. To analyse if the same effect was observed 
in this study, a three-way ANOVA was performed with the independent factors bemcentinib, 
ICB, and time (see Table 4.1) and tumour volume as the dependent variable. The ANOVA 
reported statistically significant main effects from ICB treatment and time. In addition, an 
interaction effect between ICB and time was statistically significant. By analysing the means 
for the different treatment groups (plotted in Figure 4.1 and shown in Table 10.2) it is evident 
that the time effect is associated with an increase of tumour volume, while ICB is associated 
with a decrease mainly in the second timepoint.  
Table 4.1: ANOVA on tumour volume. A three-way ANOVA with time, bemcentinib-treatment, and ICB-treatment as factors. 
The P-values are not adjusted. Interactions are indicated with a colon. 
Source of variation % of total variation P value Statistically 
significant? 
Time 43.83 <0.0001 Yes 
ICBs 11.20 0.0016 Yes 
Bem 0.004298 0.9466 No 
Time:ICB 10.85 0.0019 Yes 
Time:Bem 1.046 0.3000 No 
ICB:Bem 1.741 0.1836 No 






Figure 4.1: Tumour volume across treatment groups. Tumour volume measured in [mm3] across groups. Error bars show 
standard deviation. 
4.1.2 Spleen and Tumour Weight 
An interesting pathological development from the 4T1 breast cancer cell line is splenomegaly 
(enlarged spleen). A Pearson correlation performed on spleen and tumour weight resulted in 
a positive correlation (r = 0.8559, p<0.0001, n=40). A linear regression of spleen and tumour 






Figure 4.2: Spleen weight vs tumour weight correlation plot. Spleen weight [gram] is plotted against tumour weight [gram] 
with a fitted line and a 95% confidence interval (dotted lines).  
A three-way ANOVA conducted on the influence of three independent variables (Bemcentinib 
treatment, ICB treatment, and time) on spleen weight resulted in statistically significant main 
effects from bemcentinib treatment and statistically significant interaction effects between 
time and ICB, and time and bemcentinib (see Table 4.2). The interaction effect between 
bemcentinib and ICB is nonsignificant. This indicates that the combination group should see 
the greatest effect on spleen weight. Indeed, this is the case as shown in Figure 4.3.  
Table 4.2: ANOVA on spleen weight. Results from running a three-way ANOVA with time, bemcentinib-treatment, and ICB-
treatment as factors. The P-values are not adjusted. Interactions are indicated with a colon. 
Source of Variation % of total variation P value Statistically 
significant? 
Time 62.34 <0.0001 Yes 
ICB 1.563 0.0511 No 
Bemcentinib 3.234 0.0065 Yes 
Time:ICB 15.92 <0.0001 Yes 
Time: bemcentinib 4.015 0.0027 Yes 
ICB: bemcentinib 0.2467 0.4268 No 





A one-tailed t-test resulted in a statistically significant difference (p=0.0481) between group 
treated with ICB only and the group treated with a combination of bemcentinib and ICB.  
 
 
Figure 4.3: Spleen weight across treatment groups. Spleen weight measured in [gram] across groups. Error bars show 
standard deviation. An independent one-tailed t-test comparing combo with ICB in timepoint 2 resulted in a p value of 0.0481. 
4.2 Mass Cytometry on Spleen 
4.2.1 Timepoint 1 
Clusters found after running Phenograph on the spleen from timepoint 1 samples are shown 
in Figure 4.4. The clusters were further analysed with MEM to find cluster characteristic 
markers. Cluster cell numbers for each spleen sample was used to draw circles indicating the 
mean cluster size in each group. An extended table with means and standard deviations for 
every cluster in every group is presented in Table 10.3. An additional heatmap of median 
marker values for each cluster if presented in Figure 10.1. Finally, a two-way ANOVA with the 
independent variables bemcentinib treatment and ICB treatment was performed on the 
dependent variable cluster size. Cluster size indicates the number of cells in a given cluster. 






Figure 4.4: Spleen timepoint 1 MEM heatmap and cluster statistics. Clusters are shown as rows and markers as columns. 
Circles on the right side correspond to cell number in the treatment groups after equal subsampling. Statistical significance 
from ANOVAs performed with two independent variables (Bemcentinib treatment and ICB-treatment) on each cluster size is 
shown on the right. P-values adjusted with Bemjamini-Holberg are shown as ns (p > 0.05), * (0.05 > p), ** (0.01 > p), or *** 
(0.001 > p). Main cell phenotypes have been characterised at the far right. 
The ICB treatment shows a statistically significant decrease in a CD103- T helper cells subset 
(cluster 2), an increase in CD103+ T helper cells subset (cluster 21) and cytotoxic T cells (cluster 
8), but no significant change is found in NK cells. Two B cell subsets (cluster 6 and 14) were 
found to increase when treated with ICB and DCs (cluster 14) were found to slightly decrease 
with bemcentinib. No statistically significant change was found for TAM1 cells in either 
treatment. For type 2 (cluster 16), however, a statistically significant main effect was found 
for ICB showing an increase. Lastly, ICB was found to increase the number of cells in a MDSCs 




4.2.2 Timepoint 2 
Clusters found after running Phenograph on the spleen samples from timepoint 2 are shown 
in Figure 4.5. The clusters were further analysed with MEM to find cluster characteristic 
markers. Cluster cell numbers for each spleen sample was used to draw circles indicating the 
mean cluster size in each group. An extended table with means and standard deviations for 
every cluster in every group is presented in Table 10.5. An additional heatmap of median 
marker values for each cluster if presented in Figure 10.2. Finally, a two-way ANOVA with the 
independent variables bemcentinib treatment and ICB treatment was performed on the 
dependent variable cluster size. Cluster size indicates the number of cells in a given cluster. 






Figure 4.5: Spleen timepoint 2 MEM heatmap and cluster statistics. Each row is a cluster and each column is a marker. Circles 
on the right side correspond to cell number in the treatment groups after equal subsampling. Thus, it represents the 
proportional distribution of cells. The statistical results from a two-way ANOVA comparing the two treatments is shown on 
the right. P-values adjusted with Bemjamini-Holberg are indicated by ns (p > 0.05), * (0.05 > p), ** (0.01 > p), *** (0.001 > p). 
Main cell phenotypes have been characterised at the far right. 
Similar to timepoint 1, ICB treatment shows a statistically significant increase in a CD103+ T 
helper cell subset (cluster 11). An increase of the combo group is also shown in the second T 
helper cell subset (cluster 6), but it was not found statistically significant. Unadjusted p-values 
were just at the limit of significance for both ICB and bemcentinib (see Table 10.3).  
No statistically significant change is found for cytotoxic T cells (cluster 8) and NK cells (cluster 
13). For a small subset of CD24+ B cells (cluster 1) the number of cells were reduced by 
treatment of ICB. Both treatments were found to affect the number of DCs, however, the 
effects were opposite. While bemcentinib decreases the number of DCs, ICB treatment 




bemcentinib and ICB treatment and the effects seem to cancel each other out during 
combination (see Table 10.5). For the TAM1 (cluster 17) cells no significant change was found 
in either treatment. For type 2 however, bemcentinib (cluster 7) treatment was found lead to 
a reduction. No statistically significant effect on MDSCs was found in either treatment (cluster 
3, 19, 21), however, it is worth reporting that cluster 3, with an unadjusted p-value of 0.01 for 
an interaction effect between ICB and bemcentinib, shows a 25% reduction in the combination 
group compared to the control group, and a 50% reduction compared to the ICB treated 
group. Lastly, an unidentified phenotype CD11b+CD24+F4/80+AXL+CD11c+ population (cluster 
20) was found to be decrease by with ICB-treatment.  
4.2.3 Axl staining and density  
To visualise the distribution of AXL in the immune landscape, cells were plotted using 
calculated tSNE parameters. The clusters from Phenograph are overlaid in Figure 4.6 and 
Figure 4.7 for timepoint 1 and 2 respectively. tSNEs showing AXL expression for timepoint 1 
and 2 are shown in Figure 4.8 and tSNEs showing density are in Figure 4.9. 
 





Figure 4.7: Spleen timepoint 2 Phenograph clusters overlaid on viSNE. 
 
Figure 4.8: viSNE of spleen treatment groups and timepoints coloured by AXL intensity with binned pixels. Each dot represents 
a single cell. The colour scale is relative to each timepoint.  
In timepoint 1 in Figure 4.8 almost no AXL staining is detected, only a small island of TAM2 
cells in the lower right quadrant. In timepoint 2, however, a new island of AXL-expressing cells 
has appeared. The same TAM2 island can still be seen in now the lower right quadrant. The 




have not been phenotyped, but are characterised by AXL+ MER+ CD24+ CD11b+ CD83+ PD-1+ 
CD25+. The upper partition stain positive for CD11c and PD-L1 in addition, while the lower part 
stains positive for CTLA-4 and CD114. 
In Figure 4.9 density differences in the AXL-island are apparent depending on the treatment. 
Notably, the bemcentinib treatment seem to increase the density, while ICB treatment 
reduces it. 
 
Figure 4.9: Spleen viSNE density plot.  
4.3 Mass Cytometry on Tumour 
4.3.1 Timepoint 1 
Clusters found after running Phenograph on the tumour samples from timepoint 1 are shown 
in Figure 4.10. The clusters were further analysed with MEM to find cluster characteristic 
markers. Cluster cell numbers for each spleen sample was used to draw circles indicating the 
mean cluster size in each group. An extended table with means and standard deviations for 
every cluster in every group is presented in Table 10.7. An additional heatmap of median 
marker values for each cluster if presented in Figure 10.3. Finally, a two-way ANOVA with the 
independent variables bemcentinib treatment and ICB treatment was performed on the 
dependent variable cluster size. Cluster size indicates the number of cells in a given cluster. 







Figure 4.10: Tumour timepoint 1. MEM heatmap. Each row is a cluster and each column is a marker. Circles on the right side 
correspond to cell number in the treatment groups after equal subsampling. Thus, it represents the proportional distribution 
of cells. The statistical results from a two-way ANOVA comparing the two treatments is shown on the right. P-values adjusted 
with Bemjamini-Holberg are indicated by ns (p > 0.05), * (0.05 > p), ** (0.01 > p), *** (0.001 > p). Main cell phenotypes have 
been characterised at the far right. 
A statistically significant main effect of ICB is found to decrease the number of cells in a CD103+ 
T helper cell subset (cluster 6). No statistically significant effects were found on CTLs (cluster 
28), NK cells, B cells, and DCs. Phenograph failed to find any distinct TAM1 subset and thus 
any effect on this population in this run has not been studied. The TAM2 population was highly 
heterogenous and Phenograph partitioned the population into three different subsets 
presumably based on AXL, Arginase, and CD206 expression (data not shown). A statistically 
significant main effect of ICB is found to increase the number of cells in a MDSC subset (cluster 
4). Lastly, a statistically significant main effect of ICB is found to increase the number of cells 




4.3.2 Timepoint 2 
Clusters found after running Phenograph on the tumour samples from timepoint 2 are shown 
in Figure 4.11. The clusters were further analysed with MEM to find cluster characteristic 
markers. Cluster cell numbers for each spleen sample was used to draw circles indicating the 
mean cluster size in each group. An extended table with means and standard deviations for 
every cluster in every group is presented in Table 10.9. An additional heatmap of median 
marker values for each cluster if presented in Figure 10.4.Finally, a two-way ANOVA with the 
independent variables bemcentinib treatment and ICB treatment was performed on the 
dependent variable cluster size. Cluster size indicates the number of cells in a given cluster. 
An extended table containing a summary of each ANOVA performed is presented in Table 
10.10. 
 
Figure 4.11: Tumour timepoint 2 MEM heatmap . Each row is a cluster and each column is a marker. Circles on the right side 
correspond to cell number in the treatment groups after equal subsampling. Thus, it represents the proportional distribution 




with Bemjamini-Holberg are indicated by ns (p > 0.05), * (0.05 > p), ** (0.01 > p), *** (0.001 > p). Main cell phenotypes have 
been characterised at the far right. 
A statistically significant effect of ICB was to increase the number of cells in a CD103- T helper 
cell subset (cluster 16) and in a Ly6C+CTL subset (cluster 8). No statistically significant effects 
were found on NK cells. A statistically significant main effect of bemcentinib was, however, 
found to decrease the number of B cells and DCs. A statistically significant main effect of ICB 
was found to increase the number of TAM1s. Both bemcentinib and ICB have statistically 
significant effects that decrease the number of cells in a subtype of TAM2 (cluster 20). The 
interaction effect between bemcentinib and ICB is also significant. Due to the significant 
interaction direct interpretation is difficult and plotting the means is necessary for complete 
understanding. As shown in Figure 4.12 despite both bemcentinib and ICB alone show 
reduction of the TAM2 subset, the combination of the two does not result in any further 
reduction. 
 
Figure 4.12: Size of cluster 20 (tumour timepoint 2) in different groups plotted with means and standard deviation. Despite 
both bemcentinib and ICB show an effect on their own, the combination gives no added effect.  
For another TAM2 subset (cluster 17), both bemcentinib and ICB have statistically significant 
effects that decrease and increase the number of cells in a subtype of TAM2 (cluster 20). The 
interaction effect between bemcentinib and ICB is, however not significant. A cancellation is 






Figure 4.13: Size of cluster 17 (tumour timepoint 2) in different groups plotted with means and standard deviation. Despite 
both bemcentinib and ICB show an effect on their own, the combination leads to cancellation of the effect.  
Lastly, a statistically significant effect of bemcentinib is found to increase the number of a 
CD80+ subpopulation of MDSCs (cluster 23). 
4.3.3 Axl staining and density  
To visualise the distribution of AXL in the immune landscape, cells were plotted using 
calculated tSNE parameters. The clusters from Phenograph are overlaid in Figure 4.14 and 
Figure 4.15 for timepoint 1 and 2 respectively. tSNEs showing AXL expression for timepoint 1 






Figure 4.14: Tumour  timepoint 1 Phenograph clusters overlaid on viSNE. 
 





Figure 4.16:viSNE of tumour treatment groups and timepoints coloured by AXL intensity with binned pixels. . Each dot 
represents a single cell. The colour scale is relative to each timepoint. 
In Figure 4.16 and Figure 4.17, it is clear that the distribution of AXL+ cells changes with 
treatment.  
 






5 Discussion  
5.1 Spleen and Tumour Weight 
In section 4.1.1 we found that ICB has a statistically significant effect on tumour volume, while 
bemcentinib treatment did not. This is in contrast to the trials reported by Davidsen et al. in 
section 1.3.3 where a tumour volume of 500 mm3 was used as an endpoint and a significant 
effect of combination of ICB with bemcentinib was found [35]. As shown in Figure 1.6, the 
difference between the ICB and combo treatment seems to be more prevalent in the later 
stages of tumour development and not the early stages, which have been analysed here. It is 
therefore likely that the observed effect of bemcentinib-ICB combination on tumour growth 
is more prominent in the later stages of tumour development, which is congruent with the 
expected timecourse of immune-mediated anti-tumour effects. 
Cancer is a systemic disease and affects several organs distal to the tumour. Given the high 
correlation of spleen and tumour weight, as shown in Figure 4.2, 4T1 tumour development 
plays a role in the observed splenomegaly. Earlier, 4T1 induced splenomegaly has been 
associated with anaemia and an increase of Gr-1(Ly6G/C)+CD11b+ cells [77-79]. Interestingly, 
these markers are the same as used to phenotype myeloid derived suppressor cells (MDSCs) 
which promote tumour growth via suppression of the tumour immune response. However, 
MDSCs share these markers with some granulocyte subsets, and a functional study would be 
needed for proper classification [80]. In addition, these cells have also been classified as 
inflammatory monocytes with the potential migrate to other tissues to aid in wound healing 
[81]. This link indicates splenomegaly as a negative prognostic marker. The fact that there is a 
statistically significant difference between spleen, as shown in Figure 4.3, but not tumour 
volume might indicate that one of the benefits of combination therapy can be observed in the 
spleen. 
5.2 Mass Cytometry Analyses 
As shown in Figure 4.3, the spleens vary across the groups, thus, cluster sizes presented in the 
heatplots (Figure 4.4, Figure 4.5, Figure 4.10, and Figure 4.11) represent distribution among 
the clusters and not absolute cell counts. Thus, an observed reduction in cluster size from the 




given cell type in an organ, but rather an increase of other cell types resulting in a reduced 
ratio.  
5.2.1 Spleen Clusters 
Among the spleen samples, ICB was found to have varying effects depending on the timepoint. 
In timepoint 1 ICB was found to decrease the portion of a CD103- T helper cells subset and 
increase cytotoxic T cells (cluster 8). In timepoint 2, however, ICB alone showed no statistically 
significant increase in a similar subset. An increase in the combination group was, however, 
observed. Although not statistically significant, the unadjusted p-values for effect of both ICB 
and bemcentinib were just at the limit of statistical significance. This interesting effect found 
only in combination warrants further study. 
Bemcentinib showed both in timepoint 1 and 2 that it can decrease the amount of a 
CD80/83/86 low DC subset in the spleen. A lack of these “activation markers” could indicate a 
phenotype similar to suppressive tolerogenic DCs [82].However, ICB displays an ability to 
increase the DC proportion, and in combination these effects seem to cancel out. Thus, the 
observed reduction of DCs when treated with bemcentinib alone disappears when combined 
with ICB.  
ICB was found to increase both TAM2 and MDSCs; two potent immune suppressive cells. 
Increase of TAM2 and MDSCs was only found to be statistically significant in timepoint 1 and 
thus might only play a role in the early parts of treatment. Bemcentinib, however, was found 
to decrease the amount of TAM2 in timepoint 2.  
An MDSC subset (cluster 3) timepoint 2 was found to show an almost statistically significant 
effect (unadjusted p value 0.01, see Table 10.6) from an interaction between ICB and 
bemcentinib. Neither treatment showed a reduction when used alone, in fact both 
bemcentinib and ICB show a slight increase (not statistically significant), but when combined 
a reduction of 25% reduction compared to the control group, and a 50% reduction compared 
to the ICB treated group was seen.  
Finally, an unidentified AXL+ population (cluster 20 and 22), only found in the spleen at 
timepoint 2 in all treatment groups, was found to be directly linked to tumour development. 
Cluster 20 differed from cluster 22 in higher expression of PD-L1, and lack of expression of 




5.2.2 Tumour Clusters 
Among the tumour samples, ICB was found to affect the Th in both timepoints, but in different 
types of subset. In timepoint 1 ICB was shown to reduce the amount of CD103+ Th cells, while 
in timepoint 2 a CD103- subset was increased. Earlier it has been shown that tumour 
infiltrating CD103+ Tregs have potent suppressive capabilities [83]. However, to verify this 
cluster T regulatory cells, a functioning Treg marker, such as FOXP3 is needed. ICB also showed 
an increase the number of Ly6C+ CTLs. Ly6C has earlier been shown to be a marker of memory 
CTLs [84]. No TAM1 were classified in timepoint 1 due to Phenograph not recognising TAM1 
as a single population. In timepoint 2, however, a TAM1 population was classified and ICB was 
found to increase the number of TAM1 cells. In both timepoints three different TAM2 subsets 
were found, one of which was characterised by high AXL and CD11c (cluster 21 in timepoint1 
and 20 timepoint 2). The other two clusters did not have any clear distinction, being based on 
varying amounts of Arginase, CD206 and CD11c (data not shown). In timepoint 1 the 
bemcentinib treatment showed a reduction of the AXL+ TAM2 of almost 70% compared to the 
control. This effect was, however, not statistically significant and similar effects was not seen 
in the combination group. In timepoint 2, however, both bemcentinib and ICB showed a 
statistically significant reduction in the amount of AXL+ TAM2 cells. As shown in Figure 4.12, 
even though both treatments independently reduced the number of AXL+ TAM2 cells, no 
added effect was seen with the combination. There might however be an added functional 
effect from the inhibition of AXL. In timepoint 2, one of the other TAM2 populations (cluster 
17) was shown to be increased with ICB treatment and reduced by bemcentinib. In 
combination, these treatments seem to cancer each other out and result in the same amount 
of these cells as in the control.  
Lastly, in timepoint 2, bemcentinib was shown to increase the amount of CD80+ MDSCs 
(cluster 23). 
5.3 Sources of Error 
5.3.1 Sample Origin 
Starting with the mice, a problem is that the tumours develop at different rates in different 
mice, despite being the same strain. As mentioned in the methods, this was one of the reasons 




removed from the experiment. Moving on to the tissue dissociation, it is not certain that the 
single cell suspension is representative of the tissue. Some cell types, such as dendritic cells 
and fibroblasts, might be more strongly attached to the extra cellular matrix than epithelial 
cells and lymphocytes. The suspension was also fixed before freezing. Unproper mixing during 
fixation might fix cells together causing some cells to appear as single cells clouds while having 
doubled the intercalator content. Further, some cell types might be more affected by freezing 
and possibly fragmented more easily. 
5.3.2 Staining 
Cisplatin, which is used to stain dead cells, might also stain cells performing endocytosis, such 
as macrophages and tumour cells and cells undergoing cell division. Some granulocytes have 
also been shown to bind the X8 polymers from Fluidigm leading to unspecific staining [85]. NK 
cells and some granulocytes also have FC-receptors that can bind the constant portion of 
antibodies. The Fc-block should, however, have counteracted this. As mentioned in the 
methodological considerations, the staining from the barcoding solution is highly dependent 
on the cell type and cell count. Thus, debarcoding with wrong parameters might change the 
cell type distribution depending on sample. Some say that mass cytometry eliminates 
autofluorescence [86]. In theory this might be true, but in practice the cells are always 
contaminated with some heavy metal. Especially barium and lead are prominent sources of 
background noise. Because of the sensitivity of the instrument, heavy metals in the glass of 
glass bottles and fumes from striker flints might contaminate the sample [87].  
As shown in Figure 4.8, different cell phenotypes emerge at different timepoints. The E-group, 
which was used for titration and testing of antibodies, was also subject to this transformation. 
This variation between the timepoints (and between the tissues) indicate that a better 
approach might have been to combine samples from both timepoint and tissues and titrate 
them all at once or titrate the timepoints and tissues independently.  
5.3.3 Data Analysis 
Moving on to the data analysis, the pre-gating to select for single immune cells is also biased. 
Firstly, a subjectively determined arcsinh argument is used to transform the data. This 
transformation changes the data distribution of the channel intensities and could potentially 




made specifically for each data set. Therefore, it is drawn subjectively by the user, based on 
density estimations. No clear rules exist for how to place each gate, however, 
recommendations for some parameters are available [88]. As shown in Figure 3.4, doublets 
can still occur after the gaussian gating. This might be due to improper mixing during fixation, 
leading to cells getting fixed to each other. Before clustering was performed the sample was 
subsampled. The randomness in subsampling might have resulted in an unrepresentative 
sample. The unsupervised clustering provided by Phenograph presents very little bias, except 
for the manually chosen k parameter. It has also been shown to handle noise well and to find 
rare cell populations [72]. Phenograph has also been shown to be quite resilient and similar 
clusters are found despite variation in k [86]. The ability to find rare populations can however 





6 Concluding Remarks 
We have developed a mass cytometry panel that can be used to map multiple myeloid and 
lymphoid populations.  
AXL positive populations develop in both the spleen and tumour during tumour development 
of BALB/c mice implanted with 4T1 breast cancer cell line. Bemcentinib alone has been shown 
to reduce the amount of TAM2 cells in both spleen and tumour. In the tumour specifically, 
bemcentinib treatment counteracts an ICB (anti-PD-1 and anti-CTLA-4)-dependent increase of 
TAM2 cells. 
A population of MDSCs found in the spleen was shown to decrease only in combination of 
bemcentinib and ICB. Despite a p-value of 0.01, the result was not deemed statistically 
significant after correction for multiple testing. 
A new population of CD24+AXL+ cells in the spleen has been directly linked to tumour 
development. A CD11c+ subset of this population was found to be reduced by ICB treatment. 
7 Future Perspectives 
In each mass cytometry run a control sample was included to be able to compare all samples 
across runs. We did unfortunately not have enough time to use this data. The data acquired 
during this experiment amounts to approximately 50 000 000 events and only about 300 000 
events (~0.6%) were used in calculation of the statistics. Using the controls, all the data sets 
can be merged and cell types potentially originating from the spleen can be found in the 
tumour. The application of single cell trajectory inference methods, such as wanderlust and 
slingshot, might in this case be very interesting. In addition, with more computational power, 
larger samples can be clustered and even rarer populations and cells in between states can be 
found. In the future, the same panel can be used as is or as a template for similar studies 
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10.1 Titrated Antibody Panel 
Table 10.1: Final titrated antibody panel used during staining of mouse spleen and tumour tissue. 
Mass tag Marker Titration 1/X Concentration 
142Nd CD11c 100 NA 
143Nd CD69 100 NA 
144Nd CD115 100 NA 
145Nd CD4 400 NA 
146Nd CD8a 100 NA 
147Sm CD45 600 NA 
148Nd PD-1 100 0.5 mg/ml 
149Sm CD83 100 0.5 mg/ml 
150Nd CD24 400 NA 
151Eu CD64 200 NA 
152Sm CD3e 400 NA 
153Eu PD-L1 200 NA 
154Sm CD11b 600 NA 
155Gd G-CSF-R/CD114 100 0.5 mg/ml 
156Gd CD103 100 0.5 mg/ml 
158Gd FoxP3 100 NA 
159Tb F4/80 400 NA 
160Gd Arginase-1 100 0.5 mg/ml 
161Dy iNOS 100 NA 
162Dy Ly6C 800 NA 
163Dy CD40 200 0.5 mg/ml 
164Dy CD49b 100 NA 
165Ho CD25 100 0.5 mg/ml 
166Er CD19 200 NA 
167Er CD335 (NKp46) 400 NA 
168Er CTLA4 100 0.5 mg/ml 




170Er MerTK 100 0.5 mg/ml 
171Yb CD80 (B7.1) 400 NA 
172Yb CD86 (B7.2) 100 NA 
173Yb GM-CSF-R/CD116 200 0.5 mg/ml 
174Yb Ly6G/C 1600 NA 
176Yb Axl - MAB854 100 0.5 mg/ml 
176Yb Axl - MAB8541 100 0.5 mg/ml 
209Bi MHCII 400 NA 
 
10.2 Spleen and Tumour Statistics 
Table 10.2:Calculated means and standard deviations for spleen weight, tumour weight and tumour volume. 
Type Timepoint Group Mean  SD n 
Spleen weight 1 A 0.17 0.025 5 
Spleen weight 1 B 0.18 0.032 5 
Spleen weight 1 C 0.26 0.023 5 
Spleen weight 1 D 0.26 0.023 5 
Spleen weight 2 A 0.60 0.103 5 
Spleen weight 2 B 0.45 0.067 5 
Spleen weight 2 C 0.41 0.070 5 
Spleen weight 2 D 0.33 0.057 5 
Tumour volume 1 A 152.10 27.522 5 
Tumour volume 1 B 136.96 19.046 5 
Tumour volume 1 C 155.96 31.317 5 
Tumour volume 1 D 130.88 35.976 5 
Tumour volume 2 A 316.18 81.079 5 
Tumour volume 2 B 389.53 41.464 5 
Tumour volume 2 C 227.12 128.934 5 
Tumour volume 2 D 199.50 70.534 5 
Tumour weight 1 A 0.19 0.029 5 
Tumour weight 1 B 0.20 0.015 5 
Tumour weight 1 C 0.21 0.052 5 




Tumour weight 2 A 0.45 0.059 5 
Tumour weight 2 B 0.45 0.040 5 
Tumour weight 2 C 0.27 0.106 5 
Tumour weight 2 D 0.28 0.094 5 
 
10.3 Spleen Timepoint 1 Statistics 
10.3.1 Cluster Medians Heatmap 
 
Figure 10.1: Heatmap of median intensities for spleen in timepoint 1. Row numbers indicate cluster. Intensities have been 
transformed with an arsinh argument of 2.  
10.3.2 Cluster Means and Standard Deviation 
Table 10.3: Calculated means and standard deviations for each group in each cluster. Group A was treated with vehicle only, 
group B was treated with bemcentinib only, group C was treated with immunotherapy only (anti-CTLA-4 and anti-PD-1 
combination), and group D was treated with a combination of immunotherapy and bemcentinib.  
Group Cluster mean SD n 
A 1 3276.00 490.55 5 




C 1 2460.00 643.68 5 
D 1 2998.60 232.83 5 
A 2 2505.80 222.57 5 
B 2 2643.60 187.62 5 
C 2 1102.20 342.72 5 
D 2 1592.20 157.23 5 
A 3 822.20 251.58 5 
B 3 804.60 215.31 5 
C 3 508.80 240.17 5 
D 3 814.40 148.37 5 
A 4 567.80 165.45 5 
B 4 557.00 114.90 5 
C 4 461.20 90.13 5 
D 4 532.60 97.55 5 
A 5 1897.80 111.05 5 
B 5 1910.40 156.69 5 
C 5 1230.40 205.47 5 
D 5 1419.40 115.27 5 
A 6 2384.40 290.83 5 
B 6 1876.20 244.20 5 
C 6 3125.20 642.15 5 
D 6 2703.00 364.67 5 
A 7 1876.40 414.05 5 
B 7 2093.00 585.02 5 
C 7 3190.20 740.14 5 
D 7 2449.60 306.33 5 
A 8 1746.20 229.89 5 
B 8 1645.60 136.29 5 
C 8 1642.00 466.39 5 
D 8 1922.80 222.99 5 
A 9 1651.60 180.52 5 
B 9 1601.60 274.50 5 




D 9 1671.00 102.00 5 
A 10 50.00 15.30 5 
B 10 48.80 13.99 5 
C 10 89.80 13.10 5 
D 10 112.00 29.85 5 
A 11 451.20 80.52 5 
B 11 485.20 119.40 5 
C 11 580.60 73.96 5 
D 11 519.40 93.16 5 
A 12 477.80 259.24 5 
B 12 704.40 365.49 5 
C 12 1334.80 788.63 5 
D 12 795.20 231.21 5 
A 13 193.40 13.79 5 
B 13 201.60 27.67 5 
C 13 156.20 47.73 5 
D 13 156.60 21.43 5 
A 14 307.00 50.16 5 
B 14 259.60 39.55 5 
C 14 363.80 15.67 5 
D 14 282.20 13.41 5 
A 15 17.40 4.77 5 
B 15 21.80 6.72 5 
C 15 34.00 10.98 5 
D 15 20.60 6.31 5 
A 16 79.80 18.62 5 
B 16 79.60 15.39 5 
C 16 241.40 88.00 5 
D 16 150.60 36.74 5 
A 17 6.40 3.51 5 
B 17 4.40 2.70 5 
C 17 3.00 3.16 5 




A 18 384.40 155.58 5 
B 18 409.80 80.17 5 
C 18 524.20 117.05 5 
D 18 460.00 31.31 5 
A 19 926.40 116.09 5 
B 19 960.00 140.23 5 
C 19 868.80 117.69 5 
D 19 943.60 103.80 5 
A 20 105.00 19.53 5 
B 20 89.20 18.99 5 
C 20 135.20 13.44 5 
D 20 107.40 16.26 5 
A 21 273.00 29.09 5 
B 21 261.00 43.59 5 
C 21 342.00 41.56 5 
D 21 342.00 18.30 5 
 
10.3.3 ANOVA results 
Table 10.4: Reported results form a factorial analysis of variance to compare the main effects of bemcentinib treatment (BGB) 
and immune chekcpoint blockade (ICB, anti-PD-1 and anti-CLTA-4 combination) and the interaction effect between ICB and 
BGB on the number of cells in each cluster. 
Cluster Response Df Sum Sq Mean Sq F value Pr(>F) Benjamini-Hochberg 
(5% FDR) 
1 BGB         1 457833.8 457833.8 2.13 0.16 0.32 
1 BGB:ICB     1 278480 278480 1.30 0.27 0.43 
1 ICB         1 1682000 1682000 7.84 0.01 0.06 
1 Residuals   16 3431900.4 214493.775 NA NA 
 
2 BGB         1 492666.05 492666.05 8.68 0.01 0.05 
2 BGB:ICB     1 155056.05 155056.05 2.73 0.12 0.27 
2 ICB         1 7533781.25 7533781.25 132.80 0.00 0.00 
2 Residuals   16 907653.6 56728.35 NA NA 
 
3 BGB         1 103680 103680 2.19 0.16 0.32 
3 BGB:ICB     1 130572.8 130572.8 2.76 0.12 0.27 
3 ICB         1 115216.2 115216.2 2.43 0.14 0.31 
3 Residuals   16 757388 47336.75 NA NA 
 
4 BGB         1 4590.45 4590.45 0.32 0.58 0.71 
4 BGB:ICB     1 8446.05 8446.05 0.58 0.46 0.64 
4 ICB         1 21451.25 21451.25 1.47 0.24 0.41 





5 BGB         1 50803.2 50803.2 2.20 0.16 0.32 
5 BGB:ICB     1 38896.2 38896.2 1.68 0.21 0.38 
5 ICB         1 1677363.2 1677363.2 72.62 0.00 0.00 
5 Residuals   16 369554.4 23097.15 NA NA 
 
6 BGB         1 1082055.2 1082055.2 6.28 0.02 0.09 
6 BGB:ICB     1 9245 9245 0.05 0.82 0.85 
6 ICB         1 3071712.2 3071712.2 17.82 0.00 0.01 
6 Residuals   16 2758202.8 172387.675 NA NA 
 
7 BGB         1 343220 343220 1.19 0.29 0.45 
7 BGB:ICB     1 1145289.8 1145289.8 3.97 0.06 0.18 
7 ICB         1 3487795.2 3487795.2 12.08 0.00 0.02 
7 Residuals   16 4621285.2 288830.325 NA NA 
 
8 BGB         1 40590.05 40590.05 0.48 0.50 0.64 
8 BGB:ICB     1 181832.45 181832.45 2.15 0.16 0.32 
8 ICB         1 37411.25 37411.25 0.44 0.52 0.65 
8 Residuals   16 1354676.8 84667.3 NA NA 
 
9 BGB         1 273.8 273.8 0.01 0.93 0.93 
9 BGB:ICB     1 16473.8 16473.8 0.49 0.50 0.64 
9 ICB         1 720 720 0.02 0.89 0.90 
9 Residuals   16 543337.2 33958.575 NA NA 
 
10 BGB         1 551.25 551.25 1.48 0.24 0.41 
10 BGB:ICB     1 684.45 684.45 1.83 0.19 0.37 
10 ICB         1 13261.25 13261.25 35.54 0.00 0.00 
10 Residuals   16 5969.6 373.1 NA NA 
 
11 BGB         1 924.8 924.8 0.11 0.75 0.81 
11 BGB:ICB     1 11328.8 11328.8 1.30 0.27 0.43 
11 ICB         1 33456.2 33456.2 3.84 0.07 0.19 
11 Residuals   16 139556 8722.25 NA NA 
 
12 BGB         1 122461.25 122461.25 0.56 0.47 0.64 
12 BGB:ICB     1 733828.05 733828.05 3.35 0.09 0.22 
12 ICB         1 1122906.05 1122906.05 5.13 0.04 0.13 
12 Residuals   16 3504709.6 219044.35 NA NA 
 
13 BGB         1 92.45 92.45 0.10 0.76 0.81 
13 BGB:ICB     1 76.05 76.05 0.08 0.78 0.82 
13 ICB         1 8446.05 8446.05 9.15 0.01 0.05 
13 Residuals   16 14772.4 923.275 NA NA 
 
14 BGB         1 20801.25 20801.25 18.46 0.00 0.01 
14 BGB:ICB     1 1462.05 1462.05 1.30 0.27 0.43 
14 ICB         1 7880.45 7880.45 7.00 0.02 0.08 
14 Residuals   16 18024.8 1126.55 NA NA 
 
15 BGB         1 101.25 101.25 1.77 0.20 0.37 
15 BGB:ICB     1 396.05 396.05 6.94 0.02 0.08 
15 ICB         1 296.45 296.45 5.19 0.04 0.13 
15 Residuals   16 913.2 57.075 NA NA 
 
16 BGB         1 10351.25 10351.25 4.28 0.06 0.18 




16 ICB         1 67628.45 67628.45 27.95 0.00 0.00 
16 Residuals   16 38710.4 2419.4 NA NA 
 
17 BGB         1 4.05 4.05 0.33 0.58 0.71 
17 BGB:ICB     1 42.05 42.05 3.38 0.08 0.22 
17 ICB         1 1.25 1.25 0.10 0.76 0.81 
17 Residuals   16 199.2 12.45 NA NA 
 
18 BGB         1 1881.8 1881.8 0.17 0.69 0.79 
18 BGB:ICB     1 10035.2 10035.2 0.89 0.36 0.53 
18 ICB         1 45125 45125 3.98 0.06 0.18 
18 Residuals   16 181252.8 11328.3 NA NA 
 
19 BGB         1 14688.2 14688.2 1.02 0.33 0.49 
19 BGB:ICB     1 2121.8 2121.8 0.15 0.71 0.79 
19 ICB         1 6845 6845 0.47 0.50 0.64 
19 Residuals   16 231077.2 14442.325 NA NA 
 
20 BGB         1 2376.2 2376.2 8.01 0.01 0.06 
20 BGB:ICB     1 180 180 0.61 0.45 0.64 
20 ICB         1 2928.2 2928.2 9.87 0.01 0.04 
20 Residuals   16 4748.8 296.8 NA NA 
 
21 BGB         1 180 180 0.15 0.70 0.79 
21 BGB:ICB     1 180 180 0.15 0.70 0.79 
21 ICB         1 28125 28125 23.39 0.00 0.00 






10.4 Spleen Timepoint 2 Statistics 
10.4.1 Cluster Medians Heatmap 
 
Figure 10.2: Heatmap of median intensities for spleen in timepoint 2. Row numbers indicate cluster. Intensities have been 
transformed with an arsinh argument of 2.  
10.4.2 Cluster Means and Standard Deviation 
Table 10.5: Calculated means and standard deviations for each group in each cluster. Group A was treated with vehicle only, 
group B was treated with bemcentinib only, group C was treated with immunotherapy only (anti-CTLA-4 and anti-PD-1 
combination), and group D was treated with a combination of immunotherapy and bemcentinib. 
Group Variable mean SD n 
A 1 969.80 166.04 5 
B 1 694.60 303.38 5 
C 1 441.80 155.19 5 
D 1 432.20 100.75 5 
A 2 216.80 44.63 5 
B 2 360.00 67.42 5 
C 2 218.00 92.94 5 




A 3 2107.60 302.98 5 
B 3 2642.20 858.85 5 
C 3 3209.00 1364.49 5 
D 3 1520.20 488.72 5 
A 4 131.20 22.31 5 
B 4 79.00 8.31 5 
C 4 126.60 34.38 5 
D 4 72.60 9.86 5 
A 5 43.20 12.52 5 
B 5 57.20 21.44 5 
C 5 84.00 41.18 5 
D 5 49.40 43.79 5 
A 6 1652.80 309.54 5 
B 6 1860.40 377.07 5 
C 6 1845.00 828.76 5 
D 6 2689.40 574.66 5 
A 7 184.00 36.66 5 
B 7 93.40 34.96 5 
C 7 193.20 63.48 5 
D 7 116.40 16.15 5 
A 8 3170.60 371.33 5 
B 8 3342.80 411.97 5 
C 8 2841.60 689.60 5 
D 8 2626.60 340.92 5 
A 9 18.00 5.15 5 
B 9 14.80 2.95 5 
C 9 18.20 8.35 5 
D 9 8.80 2.68 5 
A 10 1004.00 108.22 5 
B 10 1105.80 193.64 5 
C 10 995.00 370.53 5 
D 10 1343.20 257.11 5 




B 11 134.20 15.85 5 
C 11 242.20 58.84 5 
D 11 256.20 37.33 5 
A 12 1632.60 250.35 5 
B 12 1499.60 387.79 5 
C 12 1493.00 656.88 5 
D 12 1978.40 332.05 5 
A 13 334.00 137.26 5 
B 13 316.80 63.44 5 
C 13 351.40 89.78 5 
D 13 381.80 74.34 5 
A 14 36.20 6.76 5 
B 14 36.20 4.09 5 
C 14 65.20 8.87 5 
D 14 43.40 10.01 5 
A 15 814.80 346.24 5 
B 15 959.00 315.68 5 
C 15 569.20 289.31 5 
D 15 1515.20 1139.31 5 
A 16 127.40 52.83 5 
B 16 115.60 20.34 5 
C 16 94.40 44.31 5 
D 16 55.20 14.17 5 
A 17 524.40 61.58 5 
B 17 392.00 81.96 5 
C 17 586.20 152.74 5 
D 17 467.80 69.03 5 
A 18 154.60 23.08 5 
B 18 114.20 15.25 5 
C 18 258.80 45.14 5 
D 18 147.20 26.70 5 
A 19 538.00 174.30 5 




C 19 709.20 218.95 5 
D 19 610.00 161.06 5 
A 20 694.80 352.57 5 
B 20 801.00 220.60 5 
C 20 158.80 61.18 5 
D 20 184.80 94.23 5 
A 21 3357.00 1025.62 5 
B 21 2036.60 415.78 5 
C 21 2396.80 761.80 5 
D 21 2217.40 489.31 5 
A 22 2147.40 1163.65 5 
B 22 2675.20 778.74 5 
C 22 3102.40 710.82 5 
D 22 3079.60 1011.51 5 
 
10.4.3 ANOVA results 
Table 10.6: Reported results form a factorial analysis of variance to compare the main effects of bemcentinib treatment (BGB) 
and immune chekcpoint blockade (ICB, anti-PD-1 and anti-CLTA-4 combination) and the interaction effect between ICB and 
BGB on the number of cells in each cluster. 
Cluster Response Df Sum Sq Mean Sq F value Pr(>F) Benjamini-Hochberg 
(5% FDR) 
1 BGB         1 101388.8 101388.8 2.64 0.12 0.29 
1 BGB:ICB     1 88179.2 88179.2 2.29 0.15 0.30 
1 ICB         1 780915.2 780915.2 20.30 0.00 0.00 
1 Residuals   16 615367.6 38460.475 NA NA 
 
2 BGB         1 20930.45 20930.45 5.04 0.04 0.13 
2 BGB:ICB     1 30811.25 30811.25 7.42 0.02 0.07 
2 ICB         1 29876.45 29876.45 7.20 0.02 0.07 
2 Residuals   16 66437.6 4152.35 NA NA 
 
3 BGB         1 1665222.05 1665222.05 2.27 0.15 0.30 
3 BGB:ICB     1 6179384.45 6179384.45 8.44 0.01 0.06 
3 ICB         1 530.45 530.45 0.00 0.98 0.98 
3 Residuals   16 11720368.8 732523.05 NA NA 
 
4 BGB         1 14098.05 14098.05 30.55 0.00 0.00 
4 BGB:ICB     1 4.05 4.05 0.01 0.93 0.94 
4 ICB         1 151.25 151.25 0.33 0.57 0.68 
4 Residuals   16 7383.2 461.45 NA NA 
 
5 BGB         1 530.45 530.45 0.50 0.49 0.65 
5 BGB:ICB     1 2952.45 2952.45 2.79 0.11 0.29 




5 Residuals   16 16918.8 1057.425 NA NA 
 
6 BGB         1 1383380 1383380 4.41 0.05 0.16 
6 BGB:ICB     1 506892.8 506892.8 1.62 0.22 0.40 
6 ICB         1 1303561.8 1303561.8 4.15 0.06 0.18 
6 Residuals   16 5020325.2 313770.325 NA NA 
 
7 BGB         1 35028.45 35028.45 20.43 0.00 0.00 
7 BGB:ICB     1 238.05 238.05 0.14 0.71 0.80 
7 ICB         1 1296.05 1296.05 0.76 0.40 0.56 
7 Residuals   16 27429.2 1714.325 NA NA 
 
8 BGB         1 2289.8 2289.8 0.01 0.92 0.94 
8 BGB:ICB     1 187404.8 187404.8 0.83 0.37 0.55 
8 ICB         1 1365553.8 1365553.8 6.07 0.03 0.09 
8 Residuals   16 3597506.4 224844.15 NA NA 
 
9 BGB         1 198.45 198.45 7.08 0.02 0.07 
9 BGB:ICB     1 48.05 48.05 1.71 0.21 0.38 
9 ICB         1 42.05 42.05 1.50 0.24 0.41 
9 Residuals   16 448.4 28.025 NA NA 
 
10 BGB         1 253125 253125 4.01 0.06 0.18 
10 BGB:ICB     1 75891.2 75891.2 1.20 0.29 0.47 
10 ICB         1 65208.2 65208.2 1.03 0.32 0.51 
10 Residuals   16 1010423.6 63151.475 NA NA 
 
11 BGB         1 68.45 68.45 0.05 0.83 0.91 
11 BGB:ICB     1 530.45 530.45 0.36 0.56 0.68 
11 ICB         1 62384.45 62384.45 42.58 0.00 0.00 
11 Residuals   16 23441.2 1465.075 NA NA 
 
12 BGB         1 155232.2 155232.2 0.82 0.38 0.55 
12 BGB:ICB     1 478023.2 478023.2 2.53 0.13 0.30 
12 ICB         1 143820.8 143820.8 0.76 0.40 0.56 
12 Residuals   16 3019209.6 188700.6 NA NA 
 
13 BGB         1 217.8 217.8 0.02 0.88 0.92 
13 BGB:ICB     1 2832.2 2832.2 0.31 0.58 0.68 
13 ICB         1 8487.2 8487.2 0.93 0.35 0.54 
13 Residuals   16 145808.8 9113.05 NA NA 
 
14 BGB         1 594.05 594.05 9.84 0.01 0.04 
14 BGB:ICB     1 594.05 594.05 9.84 0.01 0.04 
14 ICB         1 1638.05 1638.05 27.14 0.00 0.00 
14 Residuals   16 965.6 60.35 NA NA 
 
15 BGB         1 1485670.05 1485670.05 3.71 0.07 0.20 
15 BGB:ICB     1 803604.05 803604.05 2.01 0.18 0.33 
15 ICB         1 120590.45 120590.45 0.30 0.59 0.68 
15 Residuals   16 6405002.4 400312.65 NA NA 
 
16 BGB         1 3251.25 3251.25 2.42 0.14 0.30 
16 BGB:ICB     1 938.45 938.45 0.70 0.42 0.57 
16 ICB         1 10904.45 10904.45 8.12 0.01 0.06 
16 Residuals   16 21474.4 1342.15 NA NA 
 




17 BGB:ICB     1 245 245 0.03 0.88 0.92 
17 ICB         1 23667.2 23667.2 2.45 0.14 0.30 
17 Residuals   16 154420.8 9651.3 NA NA 
 
18 BGB         1 28880 28880 32.86 0.00 0.00 
18 BGB:ICB     1 6336.8 6336.8 7.21 0.02 0.07 
18 ICB         1 23529.8 23529.8 26.77 0.00 0.00 
18 Residuals   16 14061.6 878.85 NA NA 
 
19 BGB         1 1296.05 1296.05 0.04 0.84 0.91 
19 BGB:ICB     1 66470.45 66470.45 2.25 0.15 0.30 
19 ICB         1 15624.05 15624.05 0.53 0.48 0.64 
19 Residuals   16 472698 29543.625 NA NA 
 
20 BGB         1 21846.05 21846.05 0.47 0.50 0.65 
20 BGB:ICB     1 8040.05 8040.05 0.17 0.68 0.78 
20 ICB         1 1659456.05 1659456.05 35.77 0.00 0.00 
20 Residuals   16 742368.4 46398.025 NA NA 
 
21 BGB         1 2811750.05 2811750.05 5.50 0.03 0.11 
21 BGB:ICB     1 1627351.25 1627351.25 3.18 0.09 0.25 
21 ICB         1 759330.45 759330.45 1.49 0.24 0.41 
21 Residuals   16 8178159.2 511134.95 NA NA 
 
22 BGB 1 318781 318781 0.37 0.55 0.68 
22 BGB:ICB     1 378950 378950 0.43 0.52 0.66 
22 ICB         1 2309960 2309960 2.65 0.12 0.29 






10.5 Tumour Timepoint 1 Statistics 
10.5.1 Cluster Medians Heatmap 
 
Figure 10.3: Heatmap of median intensities for tumour in timepoint 1. Row numbers indicate cluster. Intensities have been 
transformed with an arsinh argument of 2.  
10.5.2 Cluster Means and Standard Deviation 
Table 10.7: Calculated means and standard deviations for each group in each cluster. Group A was treated with vehicle only, 
group B was treated with bemcentinib only, group C was treated with immunotherapy only (anti-CTLA-4 and anti-PD-1 
combination), and group D was treated with a combination of immunotherapy and bemcentinib. 
Group Cluster mean SD n 
A 1 29.2 7.854934755 5 
B 1 22 4.183300133 5 
C 1 25.8 9.884331035 5 
D 1 27.4 5.176871642 5 
A 2 13.4 5.176871642 5 
B 2 10.6 2.880972058 5 
C 2 21.6 14.2583309 5 




A 3 27 6.595452979 5 
B 3 15 4.636809248 5 
C 3 31.4 18.31119876 5 
D 3 25.8 6.534523701 5 
A 4 88.6 31.580057 5 
B 4 57 38.27531842 5 
C 4 449.4 295.594824 5 
D 4 403.8 132.0632424 5 
A 5 3.4 1.673320053 5 
B 5 2.2 2.48997992 5 
C 5 1.6 2.073644135 5 
D 5 1.4 0.547722558 5 
A 6 567 120.359877 5 
B 6 664.8 248.1414919 5 
C 6 267.6 49.3791454 5 
D 6 300.4 54.55089367 5 
A 7 18.2 17.69745744 5 
B 7 12.4 7.300684899 5 
C 7 2.4 2.701851217 5 
D 7 3.8 4.147288271 5 
A 8 38.6 11.86591758 5 
B 8 52 22.3159136 5 
C 8 23.4 14.38054241 5 
D 8 41.4 16.13381542 5 
A 9 86.6 30.18774586 5 
B 9 107.4 35.54293179 5 
C 9 82 44.42409256 5 
D 9 48.4 15.85244461 5 
A 10 800.6 49.83272017 5 
B 10 974.2 172.6649936 5 
C 10 945.4 341.5820546 5 
D 10 797.4 156.5464787 5 




B 11 130 12.46996391 5 
C 11 126.2 25.44995088 5 
D 11 97.8 32.59140991 5 
A 12 1.4 1.516575089 5 
B 12 13.2 21.13527856 5 
C 12 1.4 2.19089023 5 
D 12 3.6 6.426507605 5 
A 13 991.4 258.9368649 5 
B 13 1052 189.2604026 5 
C 13 1060.2 341.6272823 5 
D 13 1002.4 238.3931627 5 
A 14 4297.2 757.3686025 5 
B 14 4802.4 1086.921248 5 
C 14 3684.2 1146.471631 5 
D 14 3976.4 576.2094237 5 
A 15 159.2 46.90628956 5 
B 15 246.6 209.2864066 5 
C 15 184.6 30.07158127 5 
D 15 173.8 21.99318076 5 
A 16 489.4 188.7930083 5 
B 16 731 488.0507146 5 
C 16 433.4 204.9885363 5 
D 16 556 100.2546757 5 
A 17 890 264.8612844 5 
B 17 986.8 264.0316269 5 
C 17 2026.2 1428.962456 5 
D 17 1150.4 285.1811705 5 
A 18 592.6 189.969208 5 
B 18 688 240.9802897 5 
C 18 857.8 214.9318497 5 
D 18 970.4 101.9131984 5 
A 19 85 45.97281806 5 




C 19 55.8 23.73183516 5 
D 19 66.2 25.84956479 5 
A 20 1322.8 222.9017721 5 
B 20 1315.8 358.7724906 5 
C 20 914.6 415.3797058 5 
D 20 1112.4 377.8502349 5 
A 21 2437 1118.764274 5 
B 21 887 294.6633673 5 
C 21 2226.8 800.0135624 5 
D 21 2362.8 290.2786592 5 
A 22 3299.8 1181.197782 5 
B 22 3572.8 1873.746968 5 
C 22 2774.8 874.3879002 5 
D 22 3491.6 994.8795404 5 
A 23 3379.2 404.2984046 5 
B 23 2999.6 1223.244579 5 
C 23 2173.8 201.1285658 5 
D 23 2552 766.32728 5 
A 24 609.6 131.2680464 5 
B 24 454.6 75.49039674 5 
C 24 541.4 57.98534298 5 
D 24 500.6 66.74428815 5 
A 25 1287 264.1401143 5 
B 25 1379.2 360.8153267 5 
C 25 2457.2 854.2451053 5 
D 25 2231 267.1638074 5 
A 26 214.8 126.6143752 5 
B 26 111.6 47.52157405 5 
C 26 199.2 24.56013029 5 
D 26 182.4 37.37378761 5 
A 27 288.4 83.60801397 5 
B 27 309.8 83.49670652 5 




D 27 353 90.27181177 5 
A 28 1676.8 538.1400375 5 
B 28 2133.4 946.8501993 5 
C 28 1727.4 601.3695203 5 
D 28 1357.2 360.0523573 5 
 
10.5.3 ANOVA results 
Table 10.8: Reported results form a factorial analysis of variance to compare the main effects of bemcentinib treatment (BGB) 
and immune chekcpoint blockade (ICB, anti-PD-1 and anti-CLTA-4 combination) and the interaction effect between ICB and 
BGB on the number of cells in each cluster. 
Cluster Response Df Sum Sq Mean Sq F value Pr(>F) Bemjamini-Hochberg 
(5% FDR) 
1 BGB         1 39.2 39.2 0.77 0.39 0.69 
1 BGB:ICB     1 96.8 96.8 1.90 0.19 0.50S 
1 ICB         1 5 5 0.10 0.76 0.90 
1 Residuals   16 814.8 50.925 NA NA 
 
2 BGB         1 33.8 33.8 0.52 0.48 0.76 
2 BGB:ICB     1 0.2 0.2 0.00 0.96 0.98 
2 ICB         1 352.8 352.8 5.42 0.03 0.31 
2 Residuals   16 1042.4 65.15 NA NA 
 
3 BGB         1 387.2 387.2 3.50 0.08 0.36 
3 BGB:ICB     1 51.2 51.2 0.46 0.51 0.77 
3 ICB         1 288.8 288.8 2.61 0.13 0.44 
3 Residuals   16 1772 110.75 NA NA 
 
4 BGB         1 7449.8 7449.8 0.28 0.61 0.81 
4 BGB:ICB     1 245 245 0.01 0.93 0.97 
4 ICB         1 625872.2 625872.2 23.34 0.00 0.01 
4 Residuals   16 429117.2 26819.825 NA NA 
 
5 BGB         1 2.45 2.45 0.72 0.41 0.69 
5 BGB:ICB     1 1.25 1.25 0.37 0.55 0.80 
5 ICB         1 8.45 8.45 2.49 0.13 0.45 
5 Residuals   16 54.4 3.4 NA NA 
 
6 BGB         1 21320.45 21320.45 1.05 0.32 0.67 




6 ICB         1 550788.05 550788.05 27.04 0.00 0.01 
6 Residuals   16 325899.2 20368.7 NA NA 
 
7 BGB         1 24.2 24.2 0.25 0.63 0.81 
7 BGB:ICB     1 64.8 64.8 0.66 0.43 0.70 
7 ICB         1 744.2 744.2 7.61 0.01 0.23 
7 Residuals   16 1564 97.75 NA NA 
 
8 BGB         1 1232.45 1232.45 4.46 0.05 0.36 
8 BGB:ICB     1 26.45 26.45 0.10 0.76 0.90 
8 ICB         1 832.05 832.05 3.01 0.10 0.38 
8 Residuals   16 4423.6 276.475 NA NA 
 
9 BGB         1 204.8 204.8 0.19 0.67 0.83 
9 BGB:ICB     1 3699.2 3699.2 3.36 0.09 0.36 
9 ICB         1 5056.2 5056.2 4.60 0.05 0.36 
9 Residuals   16 17597.6 1099.85 NA NA 
 
10 BGB         1 819.2 819.2 0.02 0.89 0.97 
10 BGB:ICB     1 129283.2 129283.2 2.98 0.10 0.38 
10 ICB         1 1280 1280 0.03 0.87 0.97 
10 Residuals   16 693926.4 43370.4 NA NA 
 
11 BGB         1 217.8 217.8 0.32 0.58 0.81 
11 BGB:ICB     1 2376.2 2376.2 3.45 0.08 0.36 
11 ICB         1 540.8 540.8 0.79 0.39 0.69 
11 Residuals   16 11016.4 688.525 NA NA 
 
12 BGB         1 245 245 1.98 0.18 0.50 
12 BGB:ICB     1 115.2 115.2 0.93 0.35 0.67 
12 ICB         1 115.2 115.2 0.93 0.35 0.67 
12 Residuals   16 1980.4 123.775 NA NA 
 
13 BGB         1 9.8 9.8 0.00 0.99 1.00 
13 BGB:ICB     1 17523.2 17523.2 0.25 0.62 0.81 
13 ICB         1 460.8 460.8 0.01 0.94 0.97 
13 Residuals   16 1105633.2 69102.075 NA NA 
 
14 BGB         1 794808.45 794808.45 0.93 0.35 0.67 
14 BGB:ICB     1 56711.25 56711.25 0.07 0.80 0.91 




14 Residuals   16 13605678 850354.875 NA NA 
 
15 BGB         1 7334.45 7334.45 0.62 0.44 0.72 
15 BGB:ICB     1 12054.05 12054.05 1.02 0.33 0.67 
15 ICB         1 2808.45 2808.45 0.24 0.63 0.81 
15 Residuals   16 189556 11847.25 NA NA 
 
16 BGB         1 165802.05 165802.05 2.03 0.17 0.50 
16 BGB:ICB     1 17701.25 17701.25 0.22 0.65 0.81 
16 ICB         1 66701.25 66701.25 0.82 0.38 0.69 
16 Residuals   16 1303630.4 81476.9 NA NA 
 
17 BGB         1 758551.25 758551.25 1.34 0.26 0.60 
17 BGB:ICB     1 1182438.45 1182438.45 2.09 0.17 0.50 
17 ICB         1 2111850.05 2111850.05 3.73 0.07 0.36 
17 Residuals   16 9052504.8 565781.55 NA NA 
 
18 BGB         1 54080 54080 1.44 0.25 0.58 
18 BGB:ICB     1 369.8 369.8 0.01 0.92 0.97 
18 ICB         1 374832.2 374832.2 9.95 0.01 0.13 
18 Residuals   16 602967.2 37685.45 NA NA 
 
19 BGB         1 11.25 11.25 0.01 0.92 0.97 
19 BGB:ICB     1 396.05 396.05 0.34 0.57 0.81 
19 ICB         1 2060.45 2060.45 1.79 0.20 0.50 
19 Residuals   16 18464.8 1154.05 NA NA 
 
20 BGB         1 45505.8 45505.8 0.37 0.55 0.80 
20 BGB:ICB     1 52428.8 52428.8 0.42 0.52 0.79 
20 ICB         1 467568.2 467568.2 3.79 0.07 0.36 
20 Residuals   16 1974856 123428.5 NA NA 
 
21 BGB         1 2499245 2499245 4.85 0.04 0.36 
21 BGB:ICB     1 3553245 3553245 6.89 0.02 0.26 
21 ICB         1 2002179.2 2002179.2 3.88 0.07 0.36 
21 Residuals   16 8250973.6 515685.85 NA NA 
 
22 BGB         1 1224630.05 1224630.05 0.74 0.40 0.69 
22 BGB:ICB     1 246198.05 246198.05 0.15 0.71 0.86 
22 ICB         1 459348.05 459348.05 0.28 0.61 0.81 





23 BGB         1 2.45 2.45 0.00 1.00 1.00 
23 BGB:ICB     1 717826.05 717826.05 1.26 0.28 0.62 
23 ICB         1 3415511.25 3415511.25 5.97 0.03 0.28 
23 Residuals   16 9149978.8 571873.675 NA NA 
 
24 BGB         1 47922.05 47922.05 6.23 0.02 0.28 
24 BGB:ICB     1 16302.05 16302.05 2.12 0.16 0.50 
24 ICB         1 616.05 616.05 0.08 0.78 0.90 
24 Residuals   16 122988.8 7686.8 NA NA 
 
25 BGB         1 22445 22445 0.09 0.77 0.90 
25 BGB:ICB     1 126723.2 126723.2 0.51 0.49 0.76 
25 ICB         1 5110605 5110605 20.42 0.00 0.01 
25 Residuals   16 4004275.6 250267.225 NA NA 
 
26 BGB         1 18000 18000 3.55 0.08 0.36 
26 BGB:ICB     1 9331.2 9331.2 1.84 0.19 0.50 
26 ICB         1 3808.8 3808.8 0.75 0.40 0.69 
26 Residuals   16 81158 5072.375 NA NA 
 
27 BGB         1 24151.25 24151.25 1.04 0.32 0.67 
27 BGB:ICB     1 41314.05 41314.05 1.78 0.20 0.50 
27 ICB         1 89914.05 89914.05 3.87 0.07 0.36 
27 Residuals   16 372079.2 23254.95 NA NA 
 
28 BGB         1 9331.2 9331.2 0.02 0.88 0.97 
28 BGB:ICB     1 854497.8 854497.8 2.04 0.17 0.50 
28 ICB         1 658119.2 658119.2 1.57 0.23 0.55 






10.6 Tumour Timepoint 2 Statistics 
10.6.1 Cluster Medians Heatmap 
 
Figure 10.4: Heatmap of median intensities for tumour in timepoint 2. Row numbers indicate cluster. Intensities have been 
transformed with an arsinh argument of 2.  
10.6.2 Cluster Means and Standard Deviation 
Table 10.9: Calculated means and standard deviations for each group in each cluster. Group A was treated with vehicle only, 
group B was treated with bemcentinib only, group C was treated with immunotherapy only (anti-CTLA-4 and anti-PD-1 
combination), and group D was treated with a combination of immunotherapy and bemcentinib. 
Group Cluster mean SD n 
A 1 79.80 28.87 5 
B 1 61.00 8.60 5 
C 1 46.20 22.34 5 
D 1 37.60 7.70 5 
A 2 446.80 126.94 5 
B 2 572.60 285.51 5 
C 2 473.60 222.46 5 




A 3 396.60 70.61 5 
B 3 209.00 18.65 5 
C 3 358.40 85.26 5 
D 3 230.00 55.33 5 
A 4 4630.00 1061.04 5 
B 4 6537.40 912.06 5 
C 4 4894.60 979.31 5 
D 4 4873.40 1302.49 5 
A 5 25.80 8.58 5 
B 5 55.20 34.13 5 
C 5 18.60 5.32 5 
D 5 35.60 17.04 5 
A 6 30.00 30.01 5 
B 6 35.80 21.02 5 
C 6 22.80 13.52 5 
D 6 27.60 15.13 5 
A 7 1348.40 686.64 5 
B 7 1314.00 288.02 5 
C 7 1203.00 763.03 5 
D 7 1624.80 306.89 5 
A 8 504.00 124.83 5 
B 8 858.80 379.84 5 
C 8 2014.80 1325.63 5 
D 8 1996.40 1098.45 5 
A 9 72.20 25.78 5 
B 9 36.80 25.61 5 
C 9 72.80 40.88 5 
D 9 42.80 7.22 5 
A 10 2989.20 953.32 5 
B 10 3481.80 729.96 5 
C 10 1990.80 517.27 5 
D 10 2127.00 469.42 5 




B 11 2439.00 1627.58 5 
C 11 1080.80 84.05 5 
D 11 1265.40 358.56 5 
A 12 45.40 15.45 5 
B 12 81.60 21.22 5 
C 12 38.20 19.54 5 
D 12 33.60 10.38 5 
A 13 12.20 3.11 5 
B 13 10.40 4.34 5 
C 13 14.80 7.40 5 
D 13 18.80 14.94 5 
A 14 83.20 63.48 5 
B 14 55.60 17.70 5 
C 14 623.80 255.07 5 
D 14 443.20 307.02 5 
A 15 1744.20 590.61 5 
B 15 1385.00 254.75 5 
C 15 2150.20 431.97 5 
D 15 1712.00 513.53 5 
A 16 767.00 128.12 5 
B 16 833.40 174.71 5 
C 16 1482.00 778.64 5 
D 16 1981.40 564.37 5 
A 17 2124.20 606.13 5 
B 17 1028.00 269.96 5 
C 17 3079.60 1242.39 5 
D 17 2098.80 183.90 5 
A 18 78.20 29.83 5 
B 18 45.60 16.98 5 
C 18 46.80 14.18 5 
D 18 30.40 15.11 5 
A 19 294.60 78.75 5 




C 19 327.40 138.92 5 
D 19 367.20 91.14 5 
A 20 6233.40 1301.29 5 
B 20 2877.00 279.37 5 
C 20 3060.00 965.07 5 
D 20 3266.80 1037.66 5 
A 21 310.20 296.56 5 
B 21 531.20 208.10 5 
C 21 343.80 97.71 5 
D 21 353.40 120.14 5 
A 22 6.00 1.87 5 
B 22 8.40 2.07 5 
C 22 49.80 22.69 5 
D 22 20.00 8.63 5 
A 23 347.40 184.04 5 
B 23 1031.20 174.32 5 
C 23 416.20 170.75 5 
D 23 772.80 261.35 5 
 
10.6.3 ANOVA results 
Table 10.10: Reported results form a factorial analysis of variance to compare the main effects of bemcentinib treatment 
(BGB) and immune chekcpoint blockade (ICB, anti-PD-1 and anti-CLTA-4 combination) and the interaction effect between ICB 
and BGB on the number of cells in each cluster. 




1 BGB         1 938.45 938.45 2.56 0.13 0.32 
1 BGB:ICB     1 130.05 130.05 0.35 0.56 0.70 
1 ICB         1 4061.25 4061.25 11.08 0.00 0.03 
1 Residuals   16 5862.8 366.425 NA NA 
 
2 BGB         1 13056.05 13056.05 0.32 0.58 0.70 
2 BGB:ICB     1 27900.45 27900.45 0.68 0.42 0.60 
2 ICB         1 11472.05 11472.05 0.28 0.60 0.72 
2 Residuals   16 653169.2 40823.075 NA NA 
 




3 BGB:ICB     1 4380.8 4380.8 1.12 0.31 0.53 
3 ICB         1 369.8 369.8 0.09 0.76 0.85 
3 Residuals   16 62658.4 3916.15 NA NA 
 




3.86 0.07 0.19 




4.03 0.06 0.19 




2.12 0.16 0.35 






5 BGB         1 2691.2 2691.2 6.91 0.02 0.07 
5 BGB:ICB     1 192.2 192.2 0.49 0.49 0.64 
5 ICB         1 897.8 897.8 2.31 0.15 0.34 
5 Residuals   16 6228 389.25 NA NA 
 
6 BGB         1 140.45 140.45 0.32 0.58 0.70 
6 BGB:ICB     1 1.25 1.25 0.00 0.96 0.96 
6 ICB         1 296.45 296.45 0.68 0.42 0.60 
6 Residuals   16 7014.8 438.425 NA NA 
 
7 BGB         1 187598.45 187598.45 0.61 0.45 0.61 
7 BGB:ICB     1 260148.05 260148.05 0.85 0.37 0.58 
7 ICB         1 34196.45 34196.45 0.11 0.74 0.84 




8 BGB         1 141456.2 141456.2 0.18 0.68 0.78 
8 BGB:ICB     1 174097.8 174097.8 0.22 0.64 0.75 
8 ICB         1 8767528.2 8767528.2 11.23 0.00 0.03 
8 Residuals   16 12494964.
8 
780935.3 NA NA 
 
9 BGB         1 5346.45 5346.45 7.03 0.02 0.07 
9 BGB:ICB     1 36.45 36.45 0.05 0.83 0.88 
9 ICB         1 54.45 54.45 0.07 0.79 0.85 
9 Residuals   16 12175.2 760.95 NA NA 
 




10 BGB:ICB     1 158776.2 158776.2 0.33 0.57 0.70 
10 ICB         1 6921937.8 6921937.8 14.35 0.00 0.02 








2.43 0.14 0.33 




1.31 0.27 0.49 




2.26 0.15 0.34 
11 Residuals   16 15733040.
8 
983315.05 NA NA 
 
12 BGB         1 1248.2 1248.2 4.24 0.06 0.18 
12 BGB:ICB     1 2080.8 2080.8 7.06 0.02 0.07 
12 ICB         1 3808.8 3808.8 12.93 0.00 0.02 
12 Residuals   16 4714.4 294.65 NA NA 
 
13 BGB         1 6.05 6.05 0.08 0.78 0.85 
13 BGB:ICB     1 42.05 42.05 0.55 0.47 0.62 
13 ICB         1 151.25 151.25 1.97 0.18 0.37 
13 Residuals   16 1225.6 76.6 NA NA 
 
14 BGB         1 54184.05 54184.05 1.32 0.27 0.49 
14 BGB:ICB     1 29261.25 29261.25 0.72 0.41 0.60 




26.32 0.00 0.00 
14 Residuals   16 654661.6 40916.35 NA NA 
 
15 BGB         1 794808.45 794808.45 3.68 0.07 0.20 
15 BGB:ICB     1 7801.25 7801.25 0.04 0.85 0.88 
15 ICB         1 671611.25 671611.25 3.11 0.10 0.25 




16 BGB         1 400162.05 400162.05 1.65 0.22 0.43 
16 BGB:ICB     1 234361.25 234361.25 0.96 0.34 0.56 








16 Residuals   16 3886898.4 242931.15 NA NA 
 




10.69 0.00 0.03 
17 BGB:ICB     1 16646.45 16646.45 0.03 0.86 0.88 




10.17 0.01 0.03 
17 Residuals   16 8070484.8 504405.3 NA NA 
 
18 BGB         1 3001.25 3001.25 7.47 0.01 0.06 
18 BGB:ICB     1 328.05 328.05 0.82 0.38 0.58 
18 ICB         1 2714.45 2714.45 6.75 0.02 0.07 
18 Residuals   16 6430 401.875 NA NA 
 
19 BGB         1 5346.45 5346.45 0.59 0.45 0.61 
19 BGB:ICB     1 252.05 252.05 0.03 0.87 0.88 
19 ICB         1 7960.05 7960.05 0.88 0.36 0.58 
19 Residuals   16 144394 9024.625 NA NA 
 




13.12 0.00 0.02 




16.80 0.00 0.01 
20 ICB         1 9685536.2 9685536.2 10.25 0.01 0.03 




21 BGB         1 66470.45 66470.45 1.71 0.21 0.42 
21 BGB:ICB     1 55862.45 55862.45 1.44 0.25 0.47 
21 ICB         1 25992.05 25992.05 0.67 0.43 0.60 
21 Residuals   16 620935.6 38808.475 NA NA 
 
22 BGB         1 938.45 938.45 6.29 0.02 0.08 
22 BGB:ICB     1 1296.05 1296.05 8.68 0.01 0.04 
22 ICB         1 3836.45 3836.45 25.70 0.00 0.00 
22 Residuals   16 2388 149.25 NA NA 
 
23 BGB         1 1353040.2 1353040.2 33.47 0.00 0.00 
23 BGB:ICB     1 133824.8 133824.8 3.31 0.09 0.23 
23 ICB         1 44935.2 44935.2 1.11 0.31 0.53 
23 Residuals   16 646867.6 40429.225 NA NA 
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